On Characteristics of Burning Mouth Syndrome Patients by Acharya, Shikha
	 
On characteristics of  Burning 
Mouth Syndrome patients 
 A study based on clinical and salivary parameters 
 
 
 
Shikha Acharya 
 
 
Department of Oral Microbiology and Immunology  
Institute of Odontology 
Sahlgrenska Academy, University of Gothenburg 
 
 
 
 
 
 
 
Gothenburg 2018 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On characteristics of burning mouth syndrome patients 
-A study based on clinical and salivary parameters 
© Shikha Acharya 2018 
shikha.acharya@gu.se 
 
ISBN 978-91-629-0486-9 (Print) 
ISBN 978-91-629-0487-6 (PDF) 
Printed in Gothenburg, Sweden 2018 
Printed by BrandFactory 
  
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family and to the patients suffering from Burning Mouth Syndrome 
 
 
 
 
 
 
 Content 
Abstract ......................................................................................... 1	
Sammanfattning på svenska .........................................................3	
List of papers.................................................................................5	
Abbreviations ................................................................................7	
Overview of PhD project ...............................................................8	
1 Introduction ................................................................................9	
2 The Burning Mouth Syndrome ................................................ 10	2.1	Definition	of	BMS.........................................................................................	10	2.2	The	various	classification	systems	of	BMS	....................................	10	2.3	Epidemiology	of	BMS	................................................................................	11	2.4	Clinical	BMS	features	.................................................................................	12	2.5	Factors	associated	with	BMS.................................................................	15	2.6	Current	treatment	strategies	................................................................	20	
3  Saliva........................................................................................ 21	3.1	Salivary	glands	and	saliva	production	.............................................	21	3.2	Mechanism	of	salivary	secretion	.........................................................	22	3.3	Composition	of	saliva	................................................................................	24	3.4	Functions	of	saliva	......................................................................................	24	3.5	Whole	and	oral	mucosal	saliva.............................................................	25	3.6	Oral	mucosal	blood	flow	..........................................................................	26	3.7	Xerostomia,	hyposalivation	and	medication.................................	27	3.8	Mucins	and	the	oral	cavity......................................................................	31	
4 Main methodologies ................................................................ 35	4.1	Ethical	considerations	..............................................................................	35	4.2	Participants	....................................................................................................	35	4.3	Questionnaires..............................................................................................	38	4.4	Collection	of	whole	and	mucosal	saliva	...........................................	39	4.5	Proximity	Extension	Assay.....................................................................	40	4.6	Oligosaccharide	analysis	.........................................................................	41	4.7	Si-Lex	and	release	of	NETs	......................................................................	42	4.8	Data	and	statistical	analyses	.................................................................	42	
5 Discussion ................................................................................ 44	
6 Main findings ........................................................................... 48	
 7 Conclusion and future perspectives ........................................ 50	
8 Acknowledgements.................................................................. 51	
9 References ................................................................................ 55	
10  Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
............................................................................ 68	
  
 
 
 
 
 
 
 
 
	   1 
Abstract 
Burning Mouth Syndrome (BMS) is a condition with unknown aetiology that 
is characterised by a chronic unremitting burning sensation in the oral 
mucosa. This condition, which affects mainly middle-aged and older women, 
presents major challenges to the patients, physicians, and researchers. The 
lack of both, objective diagnostic criteria and effective treatment strategies 
renders difficulties in the management of patients suffering from BMS. The 
aims of this thesis were to: characterise the clinical symptoms and associated 
factors described by the patients; compare the whole saliva and saliva on the 
oral mucosa; and compare the salivary components in the patients with BMS 
and in age- and sex-matched controls. In Paper I it was found that 37% of 
the patients with BMS reported to have a combination of burning and 
scalding sensation as the most common BMS symptom and 45% of the 
patients reported to sense taste disturbances. The mean severity of the BMS 
symptoms experienced by the patients, measured on a visual analogue scale 
(VAS, 0-100) was 66. The patients with BMS expressed lower levels of 
satisfaction with their general and oral health, life-situation and reported 
more medications, diseases/disorders, xerostomia, allergy, skin diseases, 
bruxofacets, and less amalgam fillings than did the controls. Multiple logistic 
regression analysis, however, revealed that xerostomia and skin diseases had 
strongest association to BMS. In Paper II we compared whole saliva and 
oral mucosal saliva along with the effects of medication on the salivary flow-
rate and xerostomia in patients with BMS and in controls. It was found that 
BMS associated diseases/disorders and drug usage coincided with less saliva 
on the tongue and less whole saliva. Systemic diseases and medication usage, 
however, did not have a significant impact on xerostomia in patients with 
BMS. The effect of glycosylation of the salivary mucin MUC7 and the 
presence of inflammatory markers in patients with BMS and controls were 
examined in Paper III. Overall, the types of oligosaccharides found on 
MUC7 in BMS patients and controls were similar. However, quantitative 
analysis of the individual oligosaccharides showed lower levels of sialylated 
and fucosylated structures, especially Sialyl-Lewisx, in the patients with BMS. 
Analysis of inflammatory markers showed that patients with BMS 
represented a more heterogeneous group than the controls. This lead us to 
draw the conclusion that for some patients with BMS like symptoms, low-
grade inflammation may be a contributing factor. This expands our 
knowledge of the clinical and salivary parameters associated with BMS. 
These studies are part of a larger project to design a disease model for BMS 
that would facilitate the diagnosis and treatment of patients with BMS in the 
future.  
Keywords: Burning Mouth Syndrome, Parafunction, Skin diseases, Saliva, Drugs, 
Xerostomia, Mucins, MUC7, Sialyl-Lewisx. 
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Sammanfattning på svenska 
Burning Mouth Syndrome (BMS) är ett kroniskt smärtsyndrom som främst 
drabbar medelålders och äldre kvinnor efter klimakteriet. De som drabbas av 
BMS har munsveda och ofta smakförändringar utan synliga eller mätbara 
förändringar av den orala slemhinnan. Idag finns därför inga objektiva 
kriterier för BMS som diagnos och inga effektiva behandlingsmetoder. Detta 
gör det svårt; inte bara för den drabbade patienten, för vilken besvären 
innebär ett stort lidande, utan även för vårdgivare. Syftet med avhandlingen 
var att undersöka kliniska fynd, självrapporterade symtom och 
bakgrundsfaktorer samt saliv-relaterade förhållanden hos kvinnliga BMS-
patienter. Dessa data kan leda till bättre diagnostik och behandling i 
framtiden. Studierna omfattade frågeformulär, kliniska undersökningar, 
salivsekretion och förekomst av mukosal saliv samt analys av 
salivkomponenter och då speciellt slemproteiner s.k. muciner. Vi fann att de 
flesta patienter med BMS upplevde brännande och stickande känsla och 
nästan hälften av patienterna upplevde smakförändringarna. BMS-symtomen 
var ofta besvärande, runt 70 på en skala från 0 (inte alls svåra) till 100 
(outhärdliga). Vi fann också att patienterna var mindre nöjda med sin 
allmänna och orala hälsa och sin livssituation, jämfört med kontrollgruppen. 
Patienterna angav också att de oftare led av andra sjukdomar, att de använde 
fler mediciner, kände av muntorrhet (xerostomi) och hade fler allergier. 
Förutom ökad tandpressning (bruxism), hittade vi inga signifikanta skillnader 
för andra parafunktioner såsom tungpressning, kindlist, läpp-impressioner 
eller tandslitage. Genom multivariat analys visade sig endast xerostomi och 
hudsjukdomar vara associerade med BMS. Efterföljande analysen visade att 
BMS patienterna hade mindre saliv på tungan och helsaliv, vilket till skillnad 
från xerostomi var relaterade till förekomsten av systemiska sjukdomar och 
medicinering. En annan upptäckt var att salivens slemlager hos BMS-
patienter var förändrat.  Vi fann denna förändring på det skyddande 
kolhydratskikt som finns på ett av munhålans slemproteiner, mucinet 
MUC7. Förändringen bestod utav att en speciell typ av kolhydrater, som 
innehåller Sialyl-Lewisx, hade minskat. Sialyl-Lewisx är en kolhydrat som 
påverkar munhålans immunsystem. Minskad mängd Sialyl-Lewisx verkade 
vara oberoende utav att BMS-patienter ibland uppvisade minskad oral 
bakgrunds-inflammation och ibland ökad oral bakgrunds-inflammation, i 
jämförelse med kontrollerna. Den högre åldern hos både kontroller och 
patienter i jämförelse med normalpopulationen antogs leda till en ökad 
spridning på nivån av bakgrundsinflammationen, ett fenomen som kallas för 
”inflamm-aging”. Vi föreslår att graden av inflamm-aging kan utvärderas i 
framtiden som ett kriterium för att behandla BMS patienter. Studierna ingår i 
ett större projekt som förhoppningsvis kan bidra till att hitta en modell för 
BMS vilket i framtiden kan underlätta diagnostiken och behandlingen av 
patienter med BMS.   
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Overview of PhD project 
 
Schematic of projects comprising this thesis: Paper I investigated the clinical 
characterisation and patients described symptoms of BMS and associated factors. Paper II 
featured the comparison of saliva on the oral mucosa and whole saliva in the patients with 
BMS and in controls. It also assessed a deeper investigation into factors such as medication 
and comorbidity (for instance, systemic diseases), which could affect saliva. Paper III 
compared the glycosylation of one of the important salivary mucins, MUC7 in the patients 
and the controls. It further characterised the specific MUC7 oligosaccharides in the 
participants. Additionally, the presence of inflammatory markers and the interaction of 
specific oligosaccharides with innate immune cells, neutrophils were assessed. 
 
Burning Mouth Syndrome 
N=56 
Controls 
N=56 
Clinical examination 
Patient described symptoms 
Background factors  
  Mucosal and whole saliva 
  Oral mucosal blood flow 
  Medication 
  Comorbidity 
  Xerostomia 
Mucin MUC7 Glycosylation 
Inflammatory markers 
Glycan neutrophil  interaction 
Pap
er I
 
Paper II 
Questionnaires (General and BMS specific) 
Dental status (parafunction) 
Pressure-pain threshold (Algometer) 
 Methods 
Periotron Method® 
Laser Dopppler Flowmetry 
Questionnaires 
Gel electrophoresis 
LC-MS 
Immunoblot 
Proximity Extension Assay 
Sytox Green assay  
Studies 
Age-matched 
women 
PhD project 
*Part of PhD project but not included in the current thesis  
*Taste perception in 
patients with BMS 
Paper II 
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1 Introduction 
The oral cavity often acts as a mirror of general health and disease. Oral 
mucosal diseases affect the soft tissues of the mouth and result in 
morbidities that have physical, social and psychological consequences for the 
patients [1]. Burning, stinging or sore sensations in the oral mucosa can be 
either acute or chronic, and may share certain features. Recurrent aphthous 
stomatitis (RAS), oral lichen planus (OLP), and vesiculobullous diseases are 
common causes of mucosal soreness and pain for which visible changes in 
the oral mucosa can be observed. However, pain in the oral mucosa can also 
occur in the absence of clinical or laboratory findings e.g., in Burning Mouth 
Syndrome (BMS). BMS, which is a chronic pain syndrome, was first 
described by Portal in 1803 [2]. It mainly affects peri-/postmenopausal 
women and is characterised by an unremitting oral burning sensation often 
in combination with taste disturbances, and in absence of detectable changes 
to the oral mucosal or other clinical findings making it difficult for clinicians 
to arrive at the correct diagnosis [3]. These conditions represent a 
debilitating disorder with very poor prognosis and subjects with BMS are 
heavy consumers of healthcare resources [4]. The cause of BMS is unknown 
although a wide range of factors has been suggested [5]. As there are no 
objective criteria for the diagnosis of BMS, patient described symptoms and 
characteristics are of importance. Only scant consideration has been given to 
the potential role of saliva and none attention has been paid to the role of 
mucosal saliva in BMS. In this thesis, self-reported and clinically assessed 
characteristics, whole and mucosal saliva and salivary mucins are examined. 
Elucidation of these factors contributes to the development of a model for 
BMS, which should facilitate the development of effective treatment 
strategies. The current thesis is part of a larger project on BMS, which 
hypothesises that elderly women who have had a stressful life in parallel with 
parafunctional oral habits will later in life experience a burning sensation of 
the oral mucosa and taste disturbances as a sequel to biochemical and 
biophysical changes of the saliva. The clinical characteristics and salivary 
profile of patients with BMS are described in the following section, to put 
the work of the thesis in the context of the results from previously 
conducted studies. 
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2 The Burning Mouth Syndrome 
2.1 Definition of BMS 
A universally standardised and validated definition of BMS based on 
objective diagnostic criteria has not yet been established.  The nomenclature 
related to BMS in the literature has been a source of considerable confusion, 
as this condition has been given various synonyms, such as stomatopyrosis, 
glossopyrosis, stomatodynia, glossodynia, sore mouth, sore tongue and oral 
dysesthesia, in attempts to characterise the oral pain based on the quality 
and/or location of pain [5, 6]. The International Classification of Headache 
Disorders (ICHD-3b), third edition, beta version, describes Burning Mouth 
Syndrome [7] as an “intraoral burning or dysaesthetic sensation, recurring 
for more than 2 hours per day over more than 3 months, without clinically 
evident causative lesions”. The International Association for the Study of 
Pain (IASP) defines BMS as a chronic intra-oral burning sensation that has 
no identifiable cause in the form of either a local or systemic condition or 
disease [8]. It has been suggested that there may be discrepancy in ICHD-3b 
and IASP classification criteria of BMS [9]. Furthermore, there is a debate 
among researchers and clinicians as to whether burning mouth is a syndrome 
or a disorder [10-12]. A disorder, by definition, is a condition that manifests 
symptoms of other diseases and this occurs in some cases of BMS [12], 
whereas a syndrome is a collection of several simultaneous signs and 
symptoms of varying intensity, which also holds true for BMS [6, 13]. In this 
thesis (Papers I-III), the term BMS is treated as syndrome and the 
diagnostic criteria of BMS according to ICHD-3b criteria were applied.  
2.2 The various classification systems of BMS  
Scala et al., classified BMS into primary and secondary BMS [5]. Primary 
BMS was when the pain was idiopathic and no local or systemic cause could 
be found for the oral mucosal pain and secondary when the pain resulted 
from possible precipitating factors [5].  According to Scala et al., once such 
factors are treated, the symptoms of BMS would improve or disappear. 
Lamey and Lewis, on the other hand, have classified BMS into three 
different subtypes according to the diurnal pattern of oral symptoms [10, 14-
16]. According to Lamey and Lewis, in Type I BMS, symptoms should be 
absent upon awakening but gradually increase in severity as the day 
progresses, and it has been reported to occur in about 35% of the cases of 
BMS. About 55% of the patients experience Type II BMS, with a burning 
sensation in the oral mucosa experienced everyday, being present already in 
the morning. Type III BMS was experienced by about 10% of the patients 
involving intermittent pain with pain-free intervals [17]. Type I BMS has 
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been reported to be linked to the nutritional deficiencies and endocrine 
disorders [14], Type II BMS to chronic anxiety, and mood changes [18], and 
Type III BMS to allergic reactions to food-related products [17].   
2.3 Epidemiology of BMS  
Women are much more frequently affected by BMS than men [19] and the 
prevalence increases with age [20, 21]. BMS is most commonly seen in 
middle-aged and elderly women [20, 22] (Paper I). The prevalence of BMS 
has been reported as little as 0.1% but also large as 40% [22-25]. This huge 
span in prevalence may be due to several factors e.g., different criteria used 
for the diagnosis of BMS, variations in the age group and gender of the 
participants included in the study, variation between population and 
countries and different methods used. In an epidemiological study carried 
out in Sweden, the prevalence of BMS was 3.7% in a population of 1,427 
persons in the age range of 20-69 years [20]. Another Swedish study of 
middle-aged and elderly women reported a prevalence of 4.6% [26]. In a 
study carried out in US on 45,000 households, the prevalence of BMS was 
reported to be 0.7% based on self-reported symptoms [27]. A large 
retrospective Brazilian study carried out with more than 3,000 patients 
reported a BMS prevalence of 1% [28]. The incidence of BMS in individuals 
<50 years has been reported to be 3 per 100,000 as compared to 23 per 
100,000 for persons in the age range of 50-59 years [22]. In the same study, 
the highest incidence range was among persons in the range of 70-79 years 
of age (47 per 100, 000). A brief overview of the prevalence data reported in 
studies on BMS is given in Table 1. 
Table 1. Prevalence of BMS reported in epidemiological studies          
 
 
 
 
 
*Incidence-based study 
Reference Prevalence (%) Study Population 
Ben Aryeh et al [24] 10-40 154 
Hakeberg et al [26] 4.6 1017 
Bergdahl and Bergdahl [20] 3.7 1427 
Thorstensson and Hugosson [29] 3.4 533 
Tammiala et al [30] 14.8 431 
Lipton et al [27] 0.7 45000 
Netto et al [28] 1 3243 
Suzuki et al [31] 3 2599 
Kohorst et al [22] 0.11 482* 
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2.4 Clinical BMS features 
BMS represents a symptomatic triad with pain, xerostomia and taste 
disturbances being the most common clinical features [21] as illustrated in 
Figure 1. In addition, there are no detectable changes in the oral mucosa. 
Pain and taste disturbance are discussed below, while xerostomia will be 
discussed in the section on saliva (3.7). 
 
 
 
 
 
                                        Figure 1. Symptomatic triad associated with BMS 
2.4.1 Pain in relation to BMS 
The sensation of pain is a subjective perception and every persons 
vocabulary contains nuanced connotations regarding pain such as burning, 
stinging, and stabbing, to name a few. Oral pain is one of the cardinal 
features of BMS [5]. The pain is experienced usually at the tip and anterior 
two-thirds of the tongue, followed by the anterior hard palate and gingivae, 
lower lip, and the pharynx [32]. The pain is usually bilateral and symmetrical 
[21, 33]. Thus, pain measurement is an essential component of the disease 
assessment, including initial diagnosis [21]. Pain management and relief of 
symptoms are often significant goals of the treatment. The Visual Analogue 
Scale (VAS) and Pressure Pain Threshold (PPT) are commonly used 
measures to evaluate sensitivity to pain [34] (Paper I). In Paper I sensitivity 
to pain was measured both by using an electronic pressure algometer, and on 
a VAS by asking about perceived pain when taking a blood sample from the 
figure tip (ranging from 0= ”no pain at all” to 100= ”terrible pain”).  
 
 
BMS 
Oral mucosal pain 
Taste disturbance Xerostomia 
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2.4.1.1 Type of pain  
In a patient with BMS, the type of pain described by the patients includes 
burning, scalding, tingling, itching, swelling and/or a numb sensation [4, 23, 
35-37] (Paper I). The pain in BMS is usually described as being similar to 
toothache, although with a distinctive sensation of superficial oral burning 
[9]. A combination of burning and scalding was reported as the most 
common symptom in Paper I. The onset of pain in BMS can be idiopathic 
or related to previous events such as dental procedures and other diseases 
[21]. The intensity of pain may vary from mild to severe [38] and is usually 
within the range of 30-80 on a 100 mm VAS [14, 20, 39, 40]  (Paper I). 
About 36% of the patients in Paper I scored ³80 mm. 
2.4.1.2 Duration and intensity of pain 
BMS symptoms can persist for years or can be life-long [13, 41] (Paper I). 
The intensity of BMS pain is usually low or zero in the morning and 
gradually increases during the day [35, 39]. The symptoms may be present 
throughout day and night [33] (Paper I). None of the patients in Paper I 
reported the pain being present during the night only. The pain described by 
patients with BMS is usually long-lasting, although intermittent daily pain is 
also reported by the patients [42]. Some symptoms of BMS were reported to 
be eased by the usage of, for example, chewing gum (Paper I), mineral/tap 
water [39] (Paper I), and saliva substitute gel (Paper I). BMS patients are 
reported to have a higher threshold for pain in the oral cavity [43, 44], 
although this feature did not differ between the patients and controls in 
Paper I. In a recent study, patients with BMS showed a slightly higher PPT 
in the tongue [45]. 
2.4.1.3 Interaction of pain and sleep  
A lack of proper sleep has been postulated to increase anxiety, and 
depression, cause a loss of concentration [46], and affect the pain threshold, 
resulting in increased sensitivity to pain [47]. A study has shown that pain 
and poor sleep lead to a decreased quality of life and decreased social 
functioning [48]. There have been conflicting reports on the relationship 
between BMS and sleep. Some studies have reported that BMS pain affects 
sleep in general [39, 41, 49, 50]. Data from our BMS project (not presented 
in the attached papers) reveal that that 71% of the patients who were 
suffering from BMS reported having significant sleep disturbances, as 
compared to 37% of the controls. For chronic pain conditions such as BMS, 
it is not surprising to find disturbed sleep as comorbidity. Sleeping 
disturbance may also be related to the psychological factors associated with 
BMS [51]. The cause and effect of BMS pain and sleep phenomena have not 
14 
 
yet been established [50] and require further consideration. Psychological 
aspects of BMS are discussed separately on section 2.5.4. 
2.4.2 Taste disturbances  
Taste disturbance in the general adult population has been reported to have 
a prevalence of 0.6%-11% [29, 52-54]. The taste sensation is detected using 
five different modalities: sweet, salty, sour, bitter, and umami. Taste 
receptors located around the tongue react to all kinds of taste-active stimuli, 
and they are not restricted to the theory of a tongue map, which is based 
upon the heterogeneity of receptor fields in the mouth [55]. In contrast, 
individual sensitivities to different tastes can vary [56], and taste sensitivity 
has been suggested to decrease with aging [55].  
Altered taste sensation is one of the prominent features experienced by the 
patients suffering from BMS [6, 21, 54, 57, 58] (Paper I). Taste disturbances 
have been reported by 11%-69% of the patients [20, 21, 39] (Paper I). The 
most common taste disturbances reported are metallic, bitter or both taste 
[21, 59]. In Paper I, metallic and sour taste was the most common taste 
disturbances followed by salty, bitter, and sweet sensation reported by the 
patients. Measurements of taste perception in BMS have shown that the 
patients with BMS have a higher threshold for sourness but are indifferent to 
sweet, salty, umami and bitter stimuli [60]. In other studies, the detection 
thresholds for a sweet stimulus and for salty and bitter taste were found to 
be higher for patients with BMS than for the controls [61, 62]. Another 
study revealed BMS patients to be less sensitive than the controls for 
sweetness, sourness, saltiness and bitterness [43]. Thus, there have been 
discrepancies in the perception of the taste in the previous studies, which are 
plausibly attributed to the different methods used for taste tests and for the 
diagnosis of BMS. In an unreported study (unpublished own data), the 
whole mouth intensity test using VAS scales (0 = no sensation, 10 = 
extremely strong) for sour, sweet and metallic taste sensation was used and 
the results revealed that the patients were more sensitive than the controls to 
sour taste in lower concentrations (Figure 2). The sensation of sweet and 
metallic taste did not differ significantly between the patients with BMS and 
the controls.  
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Figure 2. Profiles of intensity testing for patients with BMS (N=51) and controls (N=51). Different 
concentrations of citric acid (modelling sourness) ranging from 0.07%-0.7%, sucrose (modelling 
sweetness) ranging from 0.2%-2% and copper sulphate (modelling metallic sensation) ranging from 
0.00015%-0.0015% were used. Plots A) Sourness; B) Sweetness; C) Metallic sensation. The y-axis 
represents mean intensity (scale 0-10 anchored both numerically and verbally) and the x-axis represents 
the concentration of stimulus.  
Patients with BMS who have a higher density of fungiform papillae [63], as 
compared to the controls, are known as ‘supertasters’ [64]. However, 
another study found out that there was no difference in the density of 
fungiform papillae between patients with BMS and controls [65]. Being 
described as a taster or a non-taster could be due to differences in taste 
sensitivity, which varies between individuals. Recently, human clusters for 
sweetness, saltiness, bitterness, umami and sourness have been defined based 
on tasting tests [56]. A classical example of distinguishing individual 
differences in taste sensitivity is the genetically inherited insensitivity to 
compounds such as phenylthiocarbamide (PTC) [66]. The sensitivity to PTC 
and other thiourea compounds, such as 6-n-propylthiouracil is dictated by 
genetic variations (for e.g. single nucleotide polymorphism) in the TAS2R38 
taste receptor gene [67, 68].  
2.5 Factors associated with BMS  
Of the factors most commonly associated with BMS (Figure 3), some will be 
discussed in the following section with an emphasis on saliva and clinical 
characteristics. 
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Figure 3. Factors commonly associated with BMS 
2.5.1 Oral parafunction  
Parafunctional habits are performed unconsciously, and are the activities of 
the stomatognatic (anatomic system comprising teeth, jaws, and associated 
soft tissues) system. Oral parafunctional habits, such as tongue thrusting, 
bruxism, and tooth clenching have been associated with the cause of burning 
pain in BMS [14, 69, 70]. BMS comorbidities, such as headache and pain in 
the temporomandibular areas, have also been reported [71]. Night bruxism 
has been noted in an observational study of patients with BMS [72]. While it 
has been proposed that parafunctional habits are associated with BMS [14, 
70], this association was not evident in Paper I.  No statistical significant 
differences were found for dental wear, tongue impressions, cheek strips or 
lip impressions between the patients and the controls, only more active 
bruxofacets (atypical facets on teeth, with flat, smooth shiny areas) in the 
patients with BMS. However, in the multiple logistic regression analysis, 
bruxofacets was not included in the final model suggesting minor influence. 
This was further confirmed in an unpublished study based on eight intra-oral 
photographs per patient and control subject, respectively (Table 2). The 
photographs, which were examined in a blinded fashion, showed more 
tongue impressions and cheek strips among the controls, and no significant 
differences were found for the dental wear and lip impression (Table 2). 
These findings suggest that parafunctional habits are not a triggering factor 
for BMS.  
 
 
 
Local factors Psychological and 
neurological factors 
Systemic factors 
  Salivary flow rate 
  Dry mouth 
  Hyposalivation 
  Taste disturbances 
  Oral parafunction 
  Improperly designed 
dentures 
  Allergies 
  Microbiological infection 
  Adverse drug effects 
  Systemic diseases 
  Haematological 
deficiencies 
  Menopause 
  Depression 
  Anxiety 
  Cancer phobia 
  Neuropathic origin 
  Impaired OHRQL 
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Table 2. Descriptive data* on parafunction in patients with BMS and controls 
 * Number of patients and controls with different types of parafunction sites, total number of sites 
registered and total participants with one or more registered parafunction. 
2.5.2 Allergy  
Although a normal oral mucosa is a prerequisite for the diagnosis of BMS, 
allergic reaction has been known to cause an oral burning sensation [73]. 
Patients with BMS have reported being allergic to denture materials, food 
additives, flavouring components and fragrant substances [17, 74-77]. 
Furthermore, remission of an oral burning sensation after the removal of the 
allergen has been observed in some studies [78, 79]. However, no significant 
association has been observed between BMS and a positive patch test [80, 
81]. In Paper I, patients with BMS reported being allergic to pollen, nickel 
and penicillin among others. However, allergies showed a weak influence on 
BMS when adjusting for other factors in a multiple logistic regression 
analysis. Allergy to denture and other dental materials has been reported to 
cause an oral burning sensation [14, 78]. In the present project, however, 
dentures were unusual, with only two patients having full denture in one jaw 
and one of them having a partial denture in the other jaw and, thus, denture 
is very unlikely the cause of the burning sensation. It also has been discussed 
that BMS is associated to possible allergy to amalgam fillings [71]. In Paper 
I, the patients with BMS were found to have fewer amalgam fillings than the 
controls. This mainly was due to replacement of amalgam with other dental 
materials. Ten of the patients with BMS had replaced their fillings but none 
of them reported to experience relief of symptoms after restorations were 
replaced. 
2.5.3 Skin diseases 
In Paper I, patients with BMS reported suffering more often than the 
controls from skin diseases such as rosacea, eczema, dry skin and psoriasis. 
Patients with BMS also reported more symptoms involving the genital 
mucosa, such as dry mucosa and lichen planus, as compared to the controls 
(Paper I). To the best of our knowledge, this association of skin diseases to 
BMS is a novel observation. 
 BMS Control p-value 
 N % N %  
Tongue impressions 18 32 30 54 0.035 
Cheek strips 14 25 29 52 0.006 
Dental wear 50 89 53 95 0.676 
Lip impressions 7 13 10 18 0.600 
Total localisations  89 41 122 55 0.003 
Participants 53 95 54 96 1 
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2.5.4 Psychological factors 
As patients with BMS do not present visible signs in the oral cavity through 
clinical or laboratory investigations, has been suggested that the clinicians 
who are unfamiliar with BMS may regard patients being emotionally unstable 
and their complaint is often not taken seriously [33]. It has been reported 
that patients experience that they are mistrusted by the healthcare givers, as 
well as their family members, which in turn may increase the patient’s 
anxiety, and ultimately their perception of pain [82, 83]. An inter-relationship 
between the chronic pain experienced by patients with psychological factors 
is presented in Figure 4. Patients with BMS often feel neglected; and 
experience depression, chronic anxiety, emotional sustainability, and anxiety 
in relation to cancer [83, 84]. A recent study investigating the psychological 
profiles of patients with BMS using SCL-R (Symptom Checklist-90- Revised 
questionnaire) revealed that BMS had significantly higher scores for 
somatisation, obsessive-compulsive disorder, depression, anxiety, and 
psychoticism than the controls [85]. The question of whether anxiety and/or 
depression are the causes or effects of BMS yet remains to be answered [33] 
A multidisciplinary approach to the patients suffering from BMS involving 
dentists, clinical psychologists and psychiatrist, thus was suggested in another 
study [83]. 
 
 
 
 
 
 
 
Figure 4: A generic schematic of inter-relationship between chronic pain, anxiety, depression and other 
emotions in patients with BMS. The greater intensity of pain may enhance anxiety, depression and other 
emotions and these factors may also aggravate the experience of chronic pain. Depression and anxiety are 
often found to be correlated to one another. Figure adapted and modified from [33]. 
 
Chronic pain 
Stress, fear 
Anxiety 
Depression 
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2.5.5 Oral health-related quality of life (OHRQL)   
Oral health is essential to general health and well-being at every stage of life. 
OHRQL captures both the clinical point of view and the individual’s 
perception of oral health related factors [86]. OHRQL reflects four aspects 
of oral health: 1) functioning aspects such as mastication and speech; 2) pain 
and discomfort, both acute and chronic; 3) psychological aspects such as 
appearance and self-esteem; and, finally, 4) social aspects such as intimacy, 
communication and social interactions. Patients suffering from BMS 
reported poor OHRQL and experienced being affected in most of these 
areas [87, 88]. Patients with BMS were often less satisfied with their general 
[48] (Paper I) and oral health [89] (Paper I) and were dissatisfied with their 
quality of life/life situation (Paper I).  
2.5.6 Menopause  
Menopause is characterised by physiological ovarian failure and hormonal 
imbalances and a study showed that removal of ovaries resulted in oral 
burning sensations in 18% of the women [90]. This notion suggested the 
role of menopause on BMS as BMS occurs in peri-/postmenopausal women 
and the occurrence of BMS before the age of 30 is rare [21, 91] (Paper I). It 
has also been suggested that altered level of female sex-hormones may 
predispose women to BMS [5]. In one study [92], increased levels of 
hormones, such as 17-b oestradiol and progesterone, were noted, which 
suggests the role of hormones in BMS. However, the functional relevance of 
these hormones for the pathogenesis of BMS remains to be studied. The 
data from Paper I does not suggest an exacerbation of post-menopausal 
symptoms among BMS patients.   
2.5.7 Neuropathic origin 
As the pain described by patients with BMS is of burning nature, BMS has 
often been suggested to be associated with a neuropathic mechanism of 
pain, where the central and/or peripheral nervous system are suggested to 
play a significant role [9, 42]. Patients with BMS are reported to have 
significantly lower densities of epithelial nerve fibres in the tongue mucosa 
[93] and reported damage in the trigeminal nerve [9, 94]. Inter-relationship 
between the pain perception and taste disturbances also has been suggested 
[95]. Furthermore, patients with BMS exhibit decreases in synaptic dopamine 
levels similar to those seen in Parkinson’s disease [96].  
 
20 
 
2.6 Current treatment strategies 
The treatment of BMS is usually focused on relieving the symptoms. The 
pharmacological options to treat BMS include administration of local and 
systemic medications such as benzodiazepines, tricyclic antidepressants, 
anticonvulsant, capsaicin, and alpha lipoic acid [97-99]. Both topical [100-
102] and systemic clonazepam [103] have been used in these patients for  the 
relief of the symptoms. However, many of the above-listed drugs are known 
to decrease the salivary flow-rate [104]. Low-level laser therapy has also been 
used in treatment of BMS [95, 97]. Hormone replacement therapy and 
cognitive behavioural therapy (either alone or together with medication) 
have been used in the treatment of BMS in past studies [33, 105, 106]. 
However, none of the previous studies have described the optimally 
effective treatment for the management of patients with BMS. 
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3  Saliva 
Saliva, salivary glands and the mechanism of saliva secretion are discussed in 
this chapter, as these distinct factors are known to be directly or indirectly 
associated with oral pain, feelings of dry mouth and taste [107, 108].  
3.1 Salivary glands and saliva production 
Saliva is a complex bodily fluid that that is often taken for granted until its 
quality or quantity deteriorates [109, 110]. Saliva is mainly produced by three 
major paired salivary glands known as the parotid, submandibular, and 
sublingual glands, which contribute approximately 90% of the total volume. 
The salivary glands are innervated and highly vascularised with a dense 
capillary network [111] providing the water for the saliva production. Most 
of the salivary components are produced by the glands, although certain 
molecules pass through the blood into the saliva through diffusion, active 
transport or ultra-filtration [112]. 
In addition to the major salivary glands there are 600-1000 minor salivary 
glands located in the labial, buccal and palatal regions. They range in size 
from 1-5 mm and contribute 6%-10% of the total 0.5-1.5 L of saliva 
produced in a 24-h period. In the oral cavity, the secretions from the 
different glands are mixed with gingival crevicular fluid, blood cells, 
microbes, cells and food debris along with naso-pharyngeal secretions [113]. 
In general, saliva secreted at rest is termed as “unstimulated whole saliva” 
(UWS) despite that this secretion is influenced by the nervous activity [113]. 
UWS flow is present in the mouth for 14-16 h/day [114]. It sustains the oral 
comfort and protection. Saliva is subjected to a circadian rhythm in terms of 
the flow-rate reaching peak flow in the mid-afternoon and a minimal flow in 
the early morning [115, 116] (Figure 5). Stimulated whole saliva (SWS) is 
secreted in response to masticatory or gustatory influence and is responsible 
for swallowing and oral clearance. Minor salivary glands secrete saliva 
spontaneously and they continue to secrete saliva at a low-rate even at night 
without the influence of any exogenous stimuli [113].  
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Figure 5. The circadian rhythm pattern of the unstimulated whole saliva (UWS) flow-rate showing the 
impacts of no sleep (solid line) and sleep (dashed line) (Adapted from [115]). 
3.2 Mechanism of salivary secretion 
The salivary gland is composed of polarised epithelial cells and consists of 
acinar cells and branched duct (intercalated, striated and excretory) cells that 
are surrounded by a dense network of capillaries. Saliva secretion is a two-
stage process [117] (Figure 6). The acinar cells have bunch of grape-like 
structures that secrete an isotonic solution. The striated duct cells modify the 
composition of the secretion by reabsorbing sodium and chloride and 
secreting bicarbonate and potassium. Water does not pass through, as the 
apical membrane of the striated duct is water impermeable. This makes 
saliva hypotonic when passed through the ducts, before entering the oral 
cavity [108]. The saliva can be categorised as serous, mucous or mixed. 
Parotid gland acinar cells produce serous saliva, while the sub-mandibular 
and sublingual glands produce mixed mucous and serous secretions [118]. 
Saliva secretion is reflex-controlled via the autonomic nervous system, which 
gets activated by the higher centres of the brain, with the sympathetic and 
parasympathetic systems working synergistically (Figure 7). Salivary glands 
are innervated by parasympathetic nerves that use acetylcholine and a 
number of non-adrenergic, non-cholinergic transmitters, such as, vasoactive 
intestinal peptide (VIP) [108, 119]. Acetylcholine, via muscarinic receptors 
(M1 and M3), is mainly responsible for the fluid secretion, while VIP, via 
VIP receptors, is mainly responsible for the protein secretion. The 
sympathetic innervation causes the release of noradrenaline that acts on α1-
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adrenoreceptors and β1-adrenoreceptors to evoke fluid secretion. It should 
be noted that although VIP is primarily responsible for protein secretion, it 
together with acetylcholine enhances both protein and fluid secretion 
(pathway not shown in figure 7). The secretory elements of minor glands are 
thought to lack a sympathetic innervation [113]. 

Figure 6. Schematic of salivary secretion (Adapted from [117, 119]). The secretion of saliva occurs in a 
two-stage process in which acinar cells secrete an isotonic solution. After passage of the isotonic solution 
through the ducts, the saliva becomes hypotonic, before being secreted into the oral cavity. The protein 
content of saliva comprises the salivary proteins secreted and synthesised by acinar cells. Proteins from 
the blood mainly enter the whole saliva in the oral cavity, mainly via the gingival crevicular fluid.  
 
Figure 7. A simplified model showing the secretion of major gland saliva in acinar cells regulated by the 
autonomic nervous system (Adapted from [108, 117, 119, 120]). The fluid secretion of saliva is dependent 
mainly upon activation of the parasympathetic system. The parasympathetic transmitter acetylcholine 
stimulates the muscarinic cholinergic (M1 and M3) receptors on the cell surface. This activates the 
inositol phospholipid (IP3) pathway mediated via phospholipase C (PLC), which in turn increases 
intracellular calcium level in the endoplasmic reticulum leading to activation of the chloride release. The 
protein secretion of saliva is dependent mainly upon sympathetic stimulation by release of the transmitter 
noradrenaline and the vasoactive intestinal peptide (VIP) from parasympathetic nerves. The noradrenaline 
binds to both α1- and β1-adrenoreceptors. Activation of β1-adrenoreceptors along with vasoactive 
intestinal peptide further induces activation of adenylyl cyclase (AC), followed by cyclic adenosine 
monophosphate that activates protein kinase A (PKA). This is followed by release of protein into saliva. 
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3.3 Composition of saliva 
The saliva entering the oral cavity consists of 99% water containing both 
organic and inorganic components. The inorganic components include 
calcium, potassium, bicarbonate and magnesium among others [121]. The 
organic salivary components include urea, ammonia, fatty acids, amino acids, 
steroid hormones, proteins and peptides, mucins, amylases, agglutinins, 
proline-rich proteins, lysozymes, peroxidases, lactoferrin, secretory IgA 
(sIgA), cystatin, histatin, and defensins [121-124]. The salivary mucins will be 
discussed in a separate section below. In the mouth, the whole saliva also 
contains cells and particles such as epithelial cells, neutrophils, 
microorganisms (bacteria, viruses, yeasts and protozoa), DNA and RNA, 
and growth factors [119, 125]. Saliva also contains gingival crevicular fluid, 
which is produced at 2-3 µl/h per tooth and can be considered as a plasma 
transudate [126]. Some of the components of saliva described here generally 
occur in small amounts and may vary with flow-rate but these components 
provide important biological functions [124]. 
3.4 Functions of saliva 
Saliva functions in: 1) moistening and lubrication; 2) taste; 3) swallowing; 4) 
protection of the oral mucosa and oesophagus; 5) protection of teeth against 
abrasion, attrition, erosion and dental caries; 6) oral clearance; and 7) 
antibacterial- and anti-viral functions, along with wound-healing functions 
[121, 127-131]. Saliva also facilitates speech and is an important mediator in 
social interactions [113]. Saliva is a non-newtonian fluid that easily spreads 
across the oral mucosal surfaces and is retained in the oral cavity [123]. 
Salivary flow is important for the removal of bacteria, buffering of saliva, 
and oral health generally. A variety of anti-microbial proteins and peptides 
keep the oral microbiota in homeostasis. The proteins in saliva aid formation 
of the pellicle, which acts as a protective layer on the oral tissues and e.g. 
reduces de-mineralisation of the teeth. Salivary constituents such as 
lactoferrin, amylase, calprotectin, proline-rich protein (PRPs), cystatin, 
histatin and sIgA have anti-microbial activities [132]. Saliva helps to break 
down food and is important for swallowing and lubrication [124, 133]. In the 
absence of saliva, the oral mucosa becomes susceptible to bacterial, viral and 
fungal infections. The lubricating properties of saliva, with the aid of the 
salivary mucins MUC5B and MUC7, help to ease the friction between tissue 
surfaces as well as mechanical wear [134]. Saliva also aids in taste perception 
by acting as a medium that dissolves food substances, and it prevents the 
taste receptors on the tongue from drying out [135]. 
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3.5 Whole and oral mucosal saliva  
3.5.1 Whole Saliva in relation to BMS 
The oral mucosa of healthy individuals is constantly bathed in saliva, which 
protects the oral mucosa from drying. The range of normal UWS flow-rate 
has been reported as 0.2-0.5 mL/min and the SWS flow-rate as 1-1.5 
mL/min [122, 124, 136-138]. Reported data on whole saliva in patients with 
BMS seems to deviate in different studies. Some studies have described a 
decreased salivary flow rate in patients with BMS [8, 14, 20, 139, 140] (Paper 
II) while others found no difference [21, 71, 141] compared to controls. In 
one study, a statistically non-significant increase in SWS and UWS in BMS 
was reported [30]. In Paper II, both UWS and SWS were found to be 
significantly reduced in BMS. Different from previous studies, factors that 
could affect the salivary secretion (for instance, medication, age, systemic 
disease) was thoroughly analysed statistically and controls were matched by 
age and gender in Paper II. The reduction in salivary flow may explain the 
decreased quality of life by interfering with daily activities such as chewing, 
swallowing and speaking (Papers I and II). Reported UWS and SWS flow-
rates in patients with BMS and controls are illustrated in Table 3. 
 
Table 3. Whole saliva flow-rates in Paper II and in the literature. 
 Saliva was measured in g/min1, parotid-gland saliva2, SD not mentioned in the article3, patients with 
secondary oral burning4, ns=not significant/p-value not mentioned in the article, -=value not given. 
3.5.2 Oral mucosal saliva in relation to BMS 
Saliva from the minor salivary glands is important for oral comfort, as it 
creates a protective lubricating layer on the mucous and contributes to the 
feeling of hydration. A correlation has been observed between the flow-rate 
of saliva from the minor salivary gland and the thickness of the residual 
saliva film remaining on the oral mucosa after swallowing, which suggests 
Reference UWS (mL/min) p-value SWS (mL/min) p-value 
 BMS (Mean±SD) 
Control 
(Mean±SD)  BMS Control  
Paper II 0.21±0.22 0.31±0.20 <0.05 1.46±0.79 1.84±0.80 <0.05 
Imura et al  [60] 0.32±0.201 0.52±0.241 <0.01 - - - 
Poon et al [8] 0.30±0.18 0.52±0.26 <0.05 1.56±0.65 2.33±1.06 0.172 
Nagler et al [142] 0.33±0.03 0.34±0.14 ns - - - 
YC Lee et al [143]  0.11±0.15 0.21±0.16 <0.05 1.17±1.25 1.21±0.73 0.875 
Lundy et al [144] - - - 0.54±0.372 0.45±0.22 - 
Spadari et al [140] 0.183 0.343 <0.01 1.78 1.7 0.7 
Soares et al [37] 0.13 ±0.09 0.16±0.13 - 1.25±0.67 1.27±0.73 - 
Das et al [145] 0.40±0.27 0.59±0.134 <0.001 0.87±0.47 0.94±0.514 0.62 
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that the minor salivary gland saliva secretion is important for sensation of 
dry mouth [146]. Oral dryness is experienced during reduced mucosal 
wetness, especially of the palate, or during salivary gland hypofunction [147]. 
Patients with hyposalivation often show reduced minor gland salivary 
secretion resulting in insufficient mucosal wetting [148]. The presence of 
saliva on the mucosal surfaces of the lips, tongue and cheeks of patients with 
BMS was first examined in Paper II. Buccal and labial saliva did not differ 
between the patients and controls, while the patients with BMS had less 
saliva on the lingual mucosa, which could be attributed to the use of saliva-
affecting drugs (Paper II). Reduced palatal and labial salivary gland 
secretions has been reported to occur in individuals with subjective oral 
dryness [149]. However, this was not seen in case of saliva on the labial 
mucosa for the patients with BMS who reported dry mouth feelings. 
Differences in e.g., the study designs, saliva collection methods, inclusion 
and exclusion criteria for the patients, and selection of outcome measures 
may be the reason for deviating finding among studies. 
3.5.3 Salivary constituents in relation to BMS 
Salivary composition in BMS has been previously reported [21, 30] showing 
quantitative differences in total protein, sIgA [60], albumin and amylase 
between BMS patients and controls [141]. Initial explorative analysis (own 
unpublished data) showed no difference in salivary total protein, epidermal 
growth factor (EGF), vascular endothelial growth factor (VEGF), 
Interleukin-8 (IL-8) and sIgA between patients with BMS and the age 
matched controls. Immunological factors e.g. different cytokines and 
interleukins as well as endocrine has previously been reported to deviate 
between BMS patients and controls in some studies [150-152] but not in all 
[99, 153]. Sub-group of patients with BMS included in the thesis, revealed a 
higher concentration of cystatin SN, as compared to the controls suggesting 
a low-level oral inflammation (unpublished observation). Patients with BMS 
displayed increased heterogeneity in the level of inflammatory biomarkers 
compared to controls in Paper III. These findings need to be validated in a 
larger cohort. 
3.6 Oral mucosal blood flow 
The microcirculatory changes in the oral cavity have been relatively 
unexplored [154], and oral mucosal blood blow in BMS patients has been 
reported in two studies but only in relation to pain in the orofacial area [155] 
and in relation to saliva (Paper II). In Paper II, there was no significant 
difference in the oral mucosal blood flows on the labial, lingual and buccal 
mucosa in patients with BMS, as compared with the controls. A significant 
negative association between the mucosal blood flow and lingual mucosal 
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saliva and whole saliva was observed in the controls. Further studies are 
needed to reveal the relevance of this observation. 
3.7 Xerostomia, hyposalivation and medication 
3.7.1 Xerostomia and hyposalivation 
Xerostomia is a subjective dry feeling in the mouth. It is derived from the 
Greek words xeros, meaning “dry” and stoma meaning “mouth” [156].  
Chronic xerostomia is a significant burden for many individuals [157, 158]. 
The clinical manifestations that are present with xerostomia are difficulties in 
swallowing, chewing, and speaking, and halitosis [131, 159]. The assessment 
of xerostomia usually involves a patient history, a dry mouth questionnaire 
[160] (Papers I and II) that enquires about symptoms, and an assessment of 
the salivary secretion. VAS is a supplementary tool that reflects the severity 
of dry mouth experienced by affected individuals. Reported xerostomia is 
one of the common findings in patients with BMS [21]. The prevalence of 
xerostomia is in the range of 5.5%-46% in a general population [158], and 
39%-75% in patients with BMS [5, 21] (Papers I and II). The xerostomia 
reported by patients in Paper I was more severe than that reported by the 
control subjects. The questions asked in relation to xerostomia are presented 
in Table 4 and are inspired from Fox et al [161].  
Table 4. Assessment of xerostomia with a questionnaire and a VAS scale. 
 
Number Question about Response alternatives and follow-up 
questions 
29 Does the amount of saliva in your 
mouth seem to be too little? 
Yes/no. If no, go straight to question 36 
30 How often does your mouth feel dry? Daily, many times/week, sometimes/week, 
sometimes/month 
31 When diurnally do you experience 
dry mouth? 
Always, nearly always, mostly at night, mostly 
in the morning, mostly during the day, mostly 
in the evening, varies 
32 Rate your dry mouth experience A VAS ranging from 0 mm to 100 mm where 
0 corresponds to “no problem at all” and 100 
to “unbearable” 
33 How long have you been suffering 
from dry mouth? 
Specify time period 
34 Does your mouth feel dry when 
eating a meal? 
Yes, no 
35 Do you have difficulties swallowing 
dry foods? 
Yes, no 
36 Do you sip liquids to aid swallowing 
dry food? 
Yes, no 
Question number 29, was the primary basis for xerostomia in the Papers I and II. 
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Hyposalivation and xerostomia are not necessarily congruent phenomena. 
While xerostomia is a subjective term, hyposalivation is an objective measure 
of the salivary secretion, whereby the UWS is ≤0.1mL/min and the SWS is 
<0.7mL/min or ≤0.7mL/min [136]. In this thesis, a flow-rate of 
≤0.7mL/min is considered hyposalivation. Patients with ≤0.1mL/min UWS 
and/or ≤0.7mL/min SWS were regarded as having hyposalivation, which 
was reported by some of the patients with BMS (Paper II). Hyposalivation 
is known to increase with age, which in turn has been related to the use of 
increased medications [158]. More patients with BMS than controls used 
prescribed medication and reported having diseases and disorders (Papers I 
and II). Patients with BMS also suffered from other comorbid 
diseases/disorders requiring medication [162] (Paper I).  The controls were 
not allowed to have serious diseases and disorders in the inclusion criteria.  
Although the effect of medication, systemic diseases and the whole saliva 
flow-rate on xerostomia could be seen on the group level, these were not 
significant contributing factors for the patients with BMS, when analysing 
the patients only (Paper II). On the contrary, although fewer controls 
experienced xerostomia compared to the patients, xerostomia experienced 
by the controls tended to be associated with the intake of medication and 
especially medication with reported-adverse effect on saliva in Paper II. It is 
also note-worthy that both patients and controls who were not taking 
medicines and who had normal salivary secretion also reported having 
xerostomia (Paper II). A brief overview of reported hyposalivation and 
xerostomia in patients with BMS is presented in Table 5. 
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3.7.2 Effects of medication on xerostomia and hyposalivation 
Dry mouth feelings linked to hyposalivation may result from the use of 
saliva affecting, xerogenic drugs [114, 163]. Many studies that have reported 
on medication-induced dry mouth feelings have only referred to subjective 
oral dryness experienced by the patients and have not taken into account the 
objective salivary flow-rate. Furthermore, medication-induced xerostomia 
has been associated not only with the type but also the number of medicines 
being taken. Medications such as anti-hypertensives (e.g. b-blockers), 
sedatives, tranquilizers and anti-psychotics are xerogenic [114]. Patients with 
BMS are commonly medicated [164] (Paper I). Xerogenic medication is 
known to reduce the salivary secretion by acting on the acinar cells [165]. 
The effect of medication on UWS in the patients with BMS has been 
described previously [8]. The number, type and dosage of medication are 
known to affect both the saliva flow-rate and the feeling of dry mouth [104, 
114]. A systematic review has shown that the frequency of xerostomia is 
related to the dose and number of medications with a higher risk of 
xerostomia occurring at advanced age as a result of medication intake [163]. 
The same study reported medication-induced xerostomia as being more 
prevalent among women than men, which also holds true for BMS cases. 
The proportions and type of medicines taken by the patients with BMS and 
controls included in the current thesis are depicted in Figure 8. 
 
 	
 
 
 
 
 
 
 
 
Figure 8. Proportions of different categories of drugs taken by the patients with BMS and by the controls 
included in the work of thesis. The three-digit code presented here is the ATC (Anatomical Therapeutic 
Chemical Classification System) code for the registered drugs. 
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3.8 Mucins and the oral cavity 
The epithelial surfaces of the body including the oral epithelium are covered 
by a protective secretion known as mucous, which plays a key role in the 
host mucosal defence [166]. The mucous is highly hydrated and contains 
prominent macromolecules known as mucins. Mucins in saliva are 
contributed by submandibular and sublingual glands and most importantly 
by the minor salivary glands located in the oral cavity [134]. The mucous and 
serous cells from the submandibular glands secrete 30% of the salivary 
mucins, while sublingual, labial and palatal glands that mainly contain 
mucous cells secrete 70% of the mucins [167, 168]. Dryness of the oral 
mucosa, burning sensation in the mouth, difficulty with speaking, and 
formation of a food bolus have all been associated with qualitative or 
quantitative alterations in salivary mucins [169]. Mucins, in general, are high-
molecular-weight glycoproteins that have a bottlebrush structure (Figure 9). 
The bottlebrush structure is due to the presence of the carbohydrate chains 
that are often clustered into highly glycosylated domains.  
 
 
Figure 9. A generic schematic of bottlebrush structure of secreted gel forming mucin glycoprotein. The 
VNTR region is rich in serine, threonine and proline (STP) that is highly O-glycosylated. There is also the 
cysteine-rich region that aid in the formation of disulphide bonds and the D domains help in polymerisa-
tion for gel formation. Figure adapted and modified from [170]. 
The mucins are categorised as: secreted (gel-forming and non-gel forming) 
and cell-surface bound mucins [171]. The mucins play a role in maintaining 
the viscoelastic properties of saliva and they actively participate in the 
bacterial aggregation and clearance from the oral cavity [169]. The lubricating 
property of mucins has been associated with the carbohydrate portion of the 
molecule [167], which facilitates the formation of a hydration shell [169]. 
The human salivary mucins comprise two structurally distinct species: 
VNTR 
Cysteine rich domain 
D-domain 
GalNAc 
GlcNAc 
Fucose 
Sialic acid 
Galactose 
VNTR Variable number tandem repeat 
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MUC5B (in-soluble, gel-forming), which was known as MG1; and MUC7 
(soluble), which was known as MG2 previously [169]. The gel-forming 
MUC5B mucins are the main lubricating components of saliva [172].  
MUC5B has been characterised as a high-molecular-weight mucin of more 
than 1 million Daltons (1MDa), consisting of about 78% carbohydrate [173]. 
MUC7 is smaller than MUC5B with molecular weight 150-200 kDa and 
contains about 68% carbohydrate [173]. Besides these classical mucins, 
salivary agglutinin is a mucin-like glycoprotein in the saliva that contains 
45% carbohydrate, with 6% sialic acid and 12% fucose [174].  
3.8.1 Mucin glycosylation 
Glycosylation is a posttranslational modification that is highly conserved and 
almost 50% of all human proteins are glycosylated [175]. In the current 
thesis, sugar, glycan or carbohydrate would be used interchangeably where 
single carbohydrate units are termed, as monosaccharide and chain of 3-10 
monosaccharide units constitute oligosaccharides. The salivary mucins are 
highly glycosylated glycoproteins that contain a wide variety of 
oligosaccharides [176]. There are two different types of glycosylation: a) N-
linked glycosylation, whereby glycans are attached to the amide nitrogens of 
asparagine side-chains and b) O-linked glycosylation, whereby glycans are 
attached to the proteins via the hydroxyl group on serine or threonine 
residues. The O-linked oligosaccharides have three distinctive parts: the core, 
backbone, and peripheral regions [177]. The N-acetylgalactosamine 
(GalNAc) residue attached to the serine or threonine of the protein 
backbone and other sugar residues, directly linked to it constitute the core 
structure. The backbone region consists alternating Galb1-3 and GlcNAcb1-
4/6 units that constitute i (linear) and I antigens (branched) [171]. O-linked 
glycans are highly heterogeneous and can vary in length with a range 
between 1-20 residues [171]. The peripheral regions of mucins contain 
individual monosaccharide such as galactose (Gal), fucose (Fuc), GalNAc, 
N-acetylglucosamine (GlcNAc) and sialic acid (NeuAc). The mucin 
structures can be further substituted with histo-blood-group antigens such as 
A, B, H, Lewisa (Lea), Lewisb (Leb), Lewisx (Lex), Lewisy (Ley), Sialyl-Lewisa 
(Si-Lea) and Sialyl-Lewisx (Si-Lex) structures [178, 179]. Sulphate is present 
linked to either Gal or GlcNAc. Sialylated and sulphated residues confer 
mucins a negative charge, which makes the mucin water-retentive together 
with the hydrophilic -OH groups of other monosaccharide residues [180]. In 
humans the expression of ABH and Lewisy/b antigens is found only in the 
secreted mucins (for e.g. in saliva) of “secretor” persons [171]. The O-linked 
glycans are highly variable in structure and the mammalian glycoproteins 
have at least eight different core structures. The most common core 
structures reported in saliva are core 1 and core 2 [181] (Paper III). A 
schematic of core structures along with different terminal glycan structures is 
presented in Figure 10 A and B respectively.  
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A 
 
B  
 
 
Figure 10. A schematic of: A) the eight different core structures B) terminal glycan epitopes. 
Changes in glycan structure can occur through incomplete glycan formation 
during synthesis or through enzymatic degradation and may thus impact 
different disease processes. Protein glycosylation has a fundamental role in 
conditions such as inflammation and cancer [182] In Sjögrens syndrome, 
reduction in sulfo-mucin was observed and this may have affected the 
hydration property as the loss of negatively charged structures has been 
linked with reduced hydration along with altered rheological properties [183]. 
Core 1 Core 2 Core 3 Core 4 
Core 6 Core 7 Core 8 Core 5 
Lewisx Lewisy Lewisa Lewisb 
Blood group A Blood group B Si-Lea Si-Lex 
Blood group H 
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In Paper III, similar types of MUC7 oligosaccharides in patients with BMS 
patients and controls were found. The most common core structures found 
in both groups were core 1 and core 2 structures. The core 2 structures 
terminated with fucose or sialic acid. The presence of Si-Lex, one of the 
terminal glycan in MUC7, was confirmed in Paper III. The levels of 
terminally fucosylated and sialylated oligosaccharide structures, especially, Si-
Lex were different between the patients with BMS and the controls (Paper 
III). The MUC7 mucin acts as a receptor for bacterial binding and Si-Lex 
works as a ligand for selectins. Therefore, an individual who fails to express 
or expressed at a reduced level Si-Lex in MUC7 may display a decreased 
leukocyte adhesion, presumably making this individual more prone to oral 
infection. Reduced Si-Lex has been implicated in ulcerated conditions in the 
oral mucosa, such as RAS [184]. Morever, the reduced levels of sialylated 
structure could impair the rheological property of mucins in the patients 
with BMS. Thus, the altered terminal sugar epitope has a regulatory function 
and entails biological consequences. 
3.8.2 Neutrophils and oligosaccharides 
The oral ecosystem maintains homeostasis through an interplay that involves 
the oral microbiota, salivary biochemistry, and host immune factors [185, 
186]. Neutrophils are a major component of the innate host response, 
constituting 40-60% of the white blood cells [187]. Neutrophils in the 
peripheral circulation can be diverted towards the mucosa and are an 
important component in maintaining oral homeostasis. Neutrophils are 
efficient phagocytes and deploy additional host-defence mechanisms by 
extruding DNA fibres in the process called as NETosis [188]. The 
extravasation (from the circulation into tissues) of polymorphonuclear 
leukocytes (neutrophils plus basophils and eosinophils) during inflammatory 
episodes involves a complex series of cellular adhesive interactions and 
signalling events [189]. Si-Lex plays an important role in the leukocyte 
extravasation into inflamed tissues by serving as the ligand for E- and P-
selectins [190, 191]. The role of neutrophils in oral mucosal diseases has 
been studied in diseases such as RAS and Behcet’s disease [192]. Mohanty et 
al observed a reduction in the amount of Si-Lex, and the ability of to form 
NETs associated with periods of ulceration in RAS [192]. Reduced levels of 
Si-Lex in RAS [184] and in BMS (Paper III) was found. Saliva has been 
suggested to produce NETs via Si-Lex stimulation [192]. In our study, Si-Lex 
standards failed to induce NETs, indicating that in our case Si-Lex are taken 
up by neutrophils by endocytocis after binding to Siglec [193] in a pathway 
to actually supress NETosis. 
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4 Main methodologies 
This section provides an overview of the inclusion and exclusion criteria for 
the patients and controls participating in this thesis and the rationale behind 
the choice of methods used.  
4.1 Ethical considerations 
Ethical considerations for studies involving human subjects are pivotal. The 
participants need to have the freedom to drop out at anytime during the 
study without any reason being given. Therefore, one needs to consider that 
there is a risk that participants will dropout, which must not affect the 
implementation of the study. The present study did not provide treatment 
measures for the patients with BMS, although they were grateful that their 
problems were taken seriously and that someone wanted to find an 
explanation for their problems. All the studies included in the thesis Papers 
(I-III) were approved by the Regional Ethical Review Board in Gothenburg, 
Sweden (Dnr. 368-19) and followed the ethical guidelines of the Helsinki 
Declaration. The participants were given written and oral information about 
the project and written informed consent was obtained from all of them. 
The identities of the patients with BMS and the controls were kept 
anonymous and the confidentiality of their data was respected throughout 
the studies.  
4.2 Participants  
The participants included in the studies of this thesis were women who had 
been diagnosed with BMS, mostly at the clinic of Oral Medicine in 
Gothenburg, Sweden. Men were not included since at start of BMS project, 
there were only three male patients diagnosed with BMS, which was too few 
to allow the analyses of gender-related differences. The detailed inclusion 
criteria for the female patients and controls are described in the Papers I 
and II. The control group consisted of age-matched women (±3 years) who 
were recruited from public and private dental clinics and staff working at the 
Institute of Odontology, Gothenburg. The exclusion and inclusion criteria 
for the patients with BMS and controls are briefly mentioned in Figure 11.  
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
Figure 11. Inclusion and exclusion criteria for the patients with BMS and controls included in the studies 
of this thesis. 
4.2.1 Haematological examination 
  
All the women underwent a complete blood count (CBC) analysis to exclude 
abnormal blood values. CBC analysis usually involves counting the numbers 
of leukocytes (white blood cells) and erythrocytes (red blood cells) per unit 
volume in a sample of venous blood. CBC was performed to avoid any 
blood related anomalies for e.g anaemia or inflammatory marker changes. 
For instance, a high white blood cell count may indicate an infection. The 
subjects’ laboratory results were compared to reference values, usually con-
sisting of upper and lower limits. Abnormally low or high count of these 
leukocytes or erythrocytes may indicate signs of inflammation or even dis-
ease. Clinical signs of inflammation include increased serum levels of acute 
phase proteins such as C-reactive protein (CRP), which was also measured in 
all the participants. The parameters examined for haematological examina-
tion is presented in Appendix 1. 
 
4.2.2 Microbiological examination 
Scraping samples from the tongue were collected and analysed to exclude 
any opportunistic pathogens in high numbers that could contribute to the 
symptoms of BMS. Opportunistic organisms, such as Candida spp., 
Staphylococcus aureus, enterococci, Pseudomonas spp., and enteric rods 
occasionally occur in low numbers in the oral cavity of healthy individuals 
[194]. The presence of such opportunists in high numbers in relation to the 
oral-resident microbiota and especially to viridans streptococci, suggests 
dysbiosis, giving symptoms that mimic those of BMS. The presence of 
opportunists was evaluated, and low numbers were detected in some patients 
and controls (Table 6). 
 
 
 
 
 
 
 
 
 
 
Controls 
Inclusion 
BMS 
Inclusion 
  Age-matched women (±3 years) 
  Normal oral mucosa/tongue with no burning 
sensation 
 
  Intraoral burning sensation 
  Anaemia or ongoing infection 
  Increased number of opportunistic microorganisms  
    on the tongue 
 Severe illnesses  
Exclusion 
   Women 
  Unremitting oral burning or stinging 
sensation > 2h per day 
  Absence of detectable changes in the 
oral mucosa 
    Anaemia or ongoing infections 
    Visible changes in the oral mucosa/tongue 
    Increased number of opportunistic 
       microorganisms on the tongue 
Exclusion 
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Table 6. Opportunistic pathogens detected in 14 patients with BMS and 6 controls 
subjects 
Microorganisms Patients with BMS Controls 
Candida spp 4 3 
Enterococci - 1 
Enteric rods 8 5 
S. aureus 1 1 
H. influenzae 1 - 
Candida was found together with enteric rods in two controls and together with S. aureus in one control 
subject. Enteric rods together with enterococci were found in one control subject.   
After the fulfilment of the diagnostic criteria a total of 56 patients and 56 
controls (Papers I and II) was included in the thesis work. The strategy for 
inclusion of patients and controls in the study is illustrated in Figure 12. All 
the patients included in the project were diagnosed by an expert in Oral 
Medicine. In order to study a group of patients like those of BMS, the 
diagnosis and inclusion and exclusion criteria is of importance since they 
could affect the results even in explorative studies such as these.  
 
Figure 12. Flow-chart showing the selection process for the patients with BMS and the controls after 
adjustment for the inclusion and the exclusion criteria 
Excluded: 
Deviating blood value (n=2) 
Oral lichen planus (n=1) 
Geographic tongue (n=1) 
Questionnaires only*** (n=1) 
Excluded: 
Deviating blood value (n=1) 
No age-match (n=2) 
Oral burning sensation (n=1) 
Finally included 
Invitation letter to 
BMS patients 
2011 
BMS patients 
(n=26) 
2012-2014 
BMS patients 
(n=56) 
Controls 
(n=56) 
BMS patients 
(n=61) 
Controls 
(n=60) 
*Clinic of Oral Medicine (n=15) 
 ***Not part of the current thesis 
Patients who gave their consent to participate 
**Media/healthcare personnel (n=20) 
(n=26) 
(n=104) 
*New patients diagnosed at the Clinic of Oral Medicine 
**Women who volunteered to participate after having heard about the  
    study from media or health-care personnel 
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4.3 Questionnaires 
All cases and controls included in this thesis completed a general 
questionnaire and five psychometric instruments. There were two extra 
questionnaires for the patients with BMS, one concerning BMS-symptoms 
and one psychometric index regarding pain. In the current PhD project, 
which is a part of a larger BMS project, the general questionnaire, the BMS 
specific-questionnaire and one psychometric instrument (OHIP-14) were 
used (Papers I and II).  
4.3.1 General questionnaire 
The general questionnaire contained 39 questions often followed by 
supplementary questions related to how, when, why and which. Questions 
regarding socio-demographic status, physical activity, relationship status, 
medications, and diseases were included. The specific questions taken from 
the general questionnaire asked to the patients with BMS and controls are 
presented in Appendix 2 (in English) and the full general questionnaire is 
presented in Appendix 3 (in Swedish). 
4.3.2 BMS questionnaire  
The questionnaire specifically applied to the patients with BMS included 16 
questions regarding the symptoms, associations connected to the debut of 
the symptoms, and other factors related to the syndrome. The questions that 
were posed to the patients with BMS were inspired by and modified from 
Bergdahl et al questionnaire [195]. The BMS questionnaire is presented in 
Appendix 4 (in English) and 5 (in Swedish). 
4.3.3 OHIP 
One of the psychometric instruments used today for measuring Oral Health 
Related Quality of life (OHRQL) is the Oral Health Impact Profile (OHIP-
49) including 49 items [196, 197]. The OHIP-49 is divided into seven 
subscales that provide a comprehensive measure of functional limitation, 
physical pain, psychological discomfort, physical disability, psychological 
disability, social disability and handicap. A short form of OHIP-49, known 
as OHIP-14 including 14 items to assess the OHRQL was used in the BMS 
project (Paper I). The Swedish version of OHIP-14 has been validated and 
found reliable [198, 199]. The responses to OHIP-14 are scored on a Likert 
scale (always, often, sometimes, seldom, never) resulting in a score of 14-70, 
with higher scores indicating poorer OHRQL. Given that BMS is a painful 
oral condition responses of the patients with BMS reflected a generally 
poorer OHRQL than the controls (Paper I). The OHIP questionnaire is 
presented in Appendix 6 (in English) and 7 (in Swedish). 
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4.4 Collection of whole and mucosal saliva 
4.4.1 Whole saliva 
The importance of saliva in health and disease is not disputed. The whole 
saliva, consisting of saliva, gingival crevicular fluid and the epithelial 
transudate has a rich content of biological substances. Saliva has therefore 
been used to study diseases such as cancer as well as autoimmune and 
endocrine diseases [200]. The role of saliva in oral mucosal diseases has been 
studied for Sjögren’s syndrome, RAS, geographic tongue, and especially in 
studies related to pain [201, 202], but to a lesser extent for BMS. Here, the 
whole and mucosal saliva of patients with BMS were examined and 
compared to those of age-matched controls (Papers II and III). 
The collection of whole saliva has not been standardised and is bound to 
limitations. The saliva secretion rate has a circadian rhythm [115, 203] with 
peaks during the late afternoon and drops to almost zero during sleep 
(Figure 3). Furthermore, O-glycosylation in human saliva significantly 
differed during the day [204]. It may therefore be important to standardise 
the time of day at which saliva is collected. To reduce any effects of diurnal 
variation, saliva was collected between 9 am and 1 pm and the participants 
were prohibited from eating or drinking 1 hour prior to saliva collection 
[205] (Paper II).  
4.4.2 Mucosal saliva 
The collection of saliva from the oral mucosa is rather complicated, as the 
saliva is viscous and secreted in small amounts. Methods using 
micropipettes, capillary tubes, and synthetic discs, and measuring coloured 
spots on chromatographic papers have been applied [206, 207]. The 
PeriotronÒ instrument, which was originally designed to measure gingival 
crevicular fluid and later minor gland salivary flow and thickness [148, 208, 
209] (Paper II), is considered to be reliable for minor fluid measurements in 
the clinical setting [210]. This method makes it possible to measure small 
volumes of fluids collected using absorbing paper, regardless of osmolarity 
and viscosity [211]. The Periotron instrument creates a voltage between two 
plates and measures the resistance of the salivary molecules in the filter 
paper. The volume collected in a 1-cm2 pre-cut absorbing filter paper is 
determined from a standard curve obtained using known volumes of water 
added to the paper. For saliva measurements, the instrument was adjusted to 
zero using a dry filter paper, which was then placed on the oral mucosa after 
drying the mucosa with cotton swabs. The mucosa was dried so as to 
remove previously secreted saliva. However, it cannot be excluded that saliva 
remains even after drying and especially on the tongue with its crypts. 
Therefore we chose to report the mucosal volume of saliva rather than the 
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secretion rate (1/cm2/min) in the oral mucosa reported in other studies 
[208].  
4.5 Proximity Extension Assay 
The Proximity Extension Assay (PEA) was used to examine inflammation-
related biomarkers, which could suggest an on-going inflammation processes 
that could differ in the patients with BMS and controls [212-214] (Paper 
III). PEA is based upon a pair of antibodies that are linked to unique 
oligonucleotides (proximity probes) that have affinity for one another. Upon 
binding the respective target protein, the probes come in close proximity and 
hybridise to each other. The hybridising oligonucleotides can be extended by 
use of DNA polymerase, and finally detected and quantified using 
quantitative Real-Time PCR. A schematic of the procedure for the PEA 
assay is given in Figure 13. 
 
Figure 13. Schematic representation of the PEA assay. One microliter of saliva is incubated with the 
PEA probes, which have affinity for each other. The oligonucleotide probes hybridise, and are further 
extended by DNA polymerase and amplified by Polymerase Chain Reaction (PCR). 
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4.6 Oligosaccharide analysis 
In this thesis, (Paper III) MUC7 glycosylation was compared between the 
patients with BMS and the controls using stimulated whole saliva samples. 
MUC7 oligosaccharides and not MUC5B analysis was prioritised as different 
MUC5B glycoforms can occur in the same glandular secretion reflecting 
extreme inter- and intra-molecular heterogeneity [215, 216]. Salivary MUC5B 
is also affected by the blood group and secretory status besides being 
heterogeneously glycosylated, making the analysis even more complex [217]. 
In contrast, salivary MUC7, is homogeneously glycosylated [218] (Paper 
III). In addition, MUC7 has been previously found to be similar in the SWS 
and UWS [219]. 
Glycans are one of the most structurally diverse molecules that are 
extensively being studied over the last few years [220] Carbohydrates also 
known as glycans consist of different monosaccharide units. The analysis of 
glycans, in analogy to genomics and proteomics is glycomics, which provides 
a comprehensive study of glycan composition and structure. Unlike proteins 
and nucleic acids the glycan biosynthesis is non-template driven, which 
means that the glycan structure is extremely heterogeneous [221, 222]. The 
carbohydrate part of the glycoprotein is responsible for the stability, activity, 
binding affinity, and specificity for other biomolecules, making analyses of 
the structures of carbohydrate analysis important in the field of glycoscience 
[222, 223]. The structural determination of carbohydrates (glycans) is 
challenging and demands highly sensitive methods. Isolation techniques such 
as Sodium dodecyl sulphate agarose polyacrylamide gel electrophoresis 
(SDS-AgPAGE) followed by electroblotting onto polyvinylidene fluoride 
(PVDF) membranes and staining by Alcian Blue allow the analysis of 
salivary mucin glycoproteins [184, 224] (Paper III). The MUC7 
oligosaccharides can be released from the glycoproteins using chemical or 
enzymatic methods, and one of the common methods to release O-glycans 
uses reductive b-elimination (Paper III). Methods such as nuclear magnetic 
resonance (NMR) and X-ray crystallography can be used for large scale 
determination of oligosaccharides [225], while the highly sensitive method 
mass spectrometry [226] (Paper III) allows detection of small amount of 
released oligosaccharides. The released oligosaccharides can be desalted and 
analysed using Liquid Chromatography Mass Spectrometry (LC-MS) [227]. 
The analysis of derived glycans using the XcaliburTM allows data visualisation 
for peak identification and quantification of relative glycan abundance [184, 
227]. Manual interpretation of MS/MS as well as comparisons of the spectra 
can be done using the freely available UniCarb-DB software [228] (Paper 
III). A schematic of the glycomic workflow is given in Figure 14. 
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Figure 14. Schematic workflow for the analysis of O-glycans  
4.7 Si-Lex and release of NETs 
The two common methods used to quantify NET release in vitro are DNA 
measurements of the supernatant fluids [229, 230] and visualisation of 
extracellular DNA by immunocytochemistry [229, 231, 232]. A study has 
shown that salivary neutrophils undergo saliva-induced NETosis in vivo 
elicited by Si-Lex [192]. The results from Paper III, which includes reduced 
Si-Lex level in BMS patients, encouraged us to test a method to determine if 
Si-Lex standards could induce NETs. Si-Lex standards did not induce NETs, 
which is in contrast to the findings from another study, where Si-Lex from 
N-glycans stimulated released of NETs [192].  
4.8 Data and statistical analyses 
Data analysis is an important task in summarising the findings of scientific 
research into an understandable context. A power analysis for Papers I-III 
was not calculated and the studies may be regarded as power generating. The 
SPSS statistical package ver. 21.0 and ver. 23.0 (SPSS, Chicago, Illinois, USA) 
(Papers I and II), GraphPad Prism V.6.04 (GraphPad Software, La Jolla, 
California, USA) (Paper III) and SAS ver. 9.4 (SAS Institute Inc, Cary, NC, 
USA) (Paper II) was used for the descriptive statistics and the statistical 
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analyses. For the questionnaire data, full Likert scale was used in all the 
analyses, even when dichotomized. All the tests were two-tailed and the pre-
chosen level of significance was p < 0.05. 
An initial descriptive statistical analysis was done to find the difference 
between groups (Paper I-III). For the normally distributed data, i.e., 
following a Gaussians distribution that gives a bell-shaped curve, parametric 
tests, such as the Students t-test, were used for the continuous variables 
(Papers I and II). For the non-normally distributed data and ordinal scales, 
non-parametric tests (e.g., Mann-Whitney U-test) (Papers I and III) were 
used. The results are presented as percentages for the categorical variables 
(Papers I and II). For the continuous variables, the mean (standard 
deviation) or median (Min; Max) per group is presented (Paper II). For the 
purpose of comparison of proportions between groups, Fisher’s exact test 
was applied. The Mantel Haenszel Chi square test was used for the ordered 
categorical variables in Paper II. For the purpose of comparison between 
more than two groups, one-way analysis of variance followed by Dunnett’s 
multiple comparison post hoc test was applied (Paper III).  
After completion of descriptive statistical analysis, further statistical analyses 
were carried out using multiple logistic (Papers I and II) and linear 
regression (Paper II), respectively. In Paper I, the multiple logistic 
regression group (BMS/Control) was used as the dependent variable and the 
significant variables from descriptive statistics were used as independent 
variables. In order to account for the potential confounders affecting salivary 
secretion and xerostomia, factors such as total number of drugs, use of drugs 
with a reported adverse effect on saliva (yes/no) and systemic disease, 
logistic regression was used with group as a dependent variable in Paper II. 
Multivariable linear regression was used to assess the variables that were 
significantly associated with UWS, SWS, buccal, labial and lingual saliva. 
Multiple logistic regression was used for the assessment of xerostomia in 
Paper II. The Odds Ratio (OR) and 95% confidence interval (CI) were 
calculated (Papers I and II).  
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5 Discussion 
This part of the thesis explores the key findings from Papers (I-III), and 
simultaneously emphasises the relevance of the findings from our studies in 
context of other studies.  
Paper I 
This study included middle-aged to elderly women, in agreement with 
previous studies [22, 233]. The results from Paper I reveal that skin diseases 
and xerostomia are commonly associated with BMS. To the best of our 
knowledge, this is the first time that skin diseases have been associated with 
BMS. This finding adds to our existing knowledge on the characteristics of 
the patients with BMS.  Xerostomia, on the other hand, is commonly 
associated with BMS [5, 21]. Almost half of the patients with BMS reported 
taste disturbances in agreement with other studies [5, 21]. BMS has often 
been associated with parafunctional habits such as lip and cheek biting, 
bruxism, and mouth breathing in many previous studies [14, 16, 70, 234]. 
However, in line with few other studies [89, 234], BMS was not found to be 
associated to parafunction, except for bruxism in the initial univariate 
analyses (Paper I). The discrepancy in the results regarding parafunctional 
habit may be explained by different methods e.g., diagnostic criteria used for 
BMS and parafunction, and lack of control group [14, 234]. In the univariate 
analysis, the patients with BMS reported having more allergies compared to 
the controls, which also has been addressed previously [17, 75]. In the 
multiple regression analysis, however, allergies were not found to have a 
significant impact on BMS. Patients with BMS in Paper I had less amalgam 
fillings compared to the controls as ten patients had exchanged their 
amalgam feelings with other dental materials. The symptoms prevailed even 
after the replacement, which suggests that amalgam fillings might not be a 
risk factor for development of BMS. This notion is supported in another 
study where, replacement of fillings did not relief the symptoms of BMS 
[71]. Patients with BMS also had more diseases and disorders, probably as a 
consequence of the inclusion criteria, and thereby also more medications. It 
is mostly likely that the cumulative effect of BMS symptoms and presence of 
other diseases and disorders is the reason why the patients rated their general 
and oral health poorer in comparison to the controls. The results from Paper 
I suggest that BMS is not a single entity disease but is instead comorbid with 
other associated factors. As the associations between comorbidities are not 
known, they warrant consideration in future studies. 
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Paper II 
Saliva is of importance in maintaining the oral homeostasis. Therefore, saliva 
in BMS patients and factors affecting saliva was investigated in Paper II. 
Overall, lower levels of saliva on the lingual mucosa, UWS, SWS, and 
unaltered buccal and labial saliva was found in the patients with BMS, as 
compared to the controls. The lower levels of UWS and SWS were related to 
the usage of drugs and systemic diseases and not to BMS per se. More of the 
patients with BMS described to have subjective xerostomia than did the 
controls. The finding of less UWS accords with the results obtained in 
previous studies [8]. To the best of our knowledge, no previous studies have 
reported significantly reduced SWS in BMS. An increase in SWS has been 
reported in one study previously [30], which, however, included patients with 
fungal infection. Paper II revealed that significantly more patients with BMS 
had hyposalivation due to very low SWS secretion rate compared to the 
controls, which could not be explained by medication, age or systemic 
disease. It is well known that diseases, and especially medication, affect the 
salivary secretion, including the dosage and number of such medications 
[114]. Although medication was related to less saliva, it was not found to be 
a causative factor for xerostomia in the patients with BMS. On the contrary, 
drug usage tended to be associated with xerostomia in the controls. Other 
factors, for instance, psychological factors also need to be taken into 
consideration while assessing xerostomia. For instance, UWS hyposalivation 
and xerostomia were not only related to medication but also psychological 
factors such as anxiety, depression and stress [235]. 
Age 
Old age and extent of medication are often related and they have important 
impacts on the quality and quantity of saliva [236, 237]. With increasing age 
come the consequences of, alteration in gland size. Both major and minor 
salivary glands undergo age-related structural changes, for instance loss of 
saliva producing acini cells. Some studies but not all have shown that the 
aging process leads to reduced salivary flow rate [237, 238]. According to a 
meta-analysis, aging results in a general decreased salivary flow-rate [239], 
which could always not be explained by medication. An age related reduced 
parenchyma of the salivary submandibular gland might implicate an impaired 
gland function resulting in reduced volume of saliva produced [237]. In 
Paper II, UWS (but not SWS) was affected by age in the patients. This 
differential effect may be due to SWS being mostly produced from the 
serous parotid glands. Aging might affect the salivary secretion in a gland 
specific manner where the more mucous submandibular and sublingual 
glands, which contribute most of the UWS, may be more affected by age 
[237]. Parotid gland, for instance remains stable in healthy non-medicated 
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people [240]. Saliva on the oral mucosa (labial, buccal and lingual) remained 
unaffected by age (Paper II) in contrast to other studies [239].  
Comorbidity and medication 
With increasing age, comes more ailments, such as diseases and disorders 
[241]. This in turn is indicative of a higher intake of medications, and even 
polypharmacy [242]. A previous study has shown that taking two more or 
medication can affect salivary secretion [8]. Additionally, it has been reported 
that some drugs might not have an affect on saliva when taken individually 
but exhibit xerogenic effect when used in combination [104, 242]. In our 
study, patients with BMS also took medicines, not prescribed by the 
physicians. Whether such preparations in combination with other drugs 
could affect the salivary flow-rate is not known. Patients with BMS used 
drugs such as psychoanaleptics, psycholeptics, diuretic and analgesics, which 
may decrease the saliva secreted. Furthermore, many of these patients with 
BMS used drugs, with a known reported adverse effect on the salivary 
secretion. The drugs with a reported adverse effect on saliva actually affected 
the salivary secretion in both patients and the controls, in agreement with 
other studies [104, 236]. 
Xerostomia  
A feeling of oral dryness does not necessarily reflect reduced salivary output 
[37]. This was further confirmed in the present study, where there were 
patients with BMS and controls who had a normal salivary flow-rate but 
nevertheless complained of xerostomia. There were also patients and 
controls with hyposalivation who did not complain of xerostomia, which is 
in agreement with previous studies [37]. Even if the quantity of saliva could 
not explain xerostomia it is possible that the quality of saliva is of 
importance and especially the lubricating and protecting salivary mucins 
[183, 243].  
Paper III 
In Paper III, an analysis of the overall mucin MUC7 glycosylation was 
performed to see, if glycosylation differed between the patients with BMS 
and the controls. Overall, the types of MUC7 oligosaccharides were similar 
between the patients with BMS and the controls. However, a significant 
reduction in levels of terminal sialylated and fucosylated structures such as 
Si-Lex was found in patients with BMS in comparison to the controls. 
Reductions in Si-Lex and NeuAc may lead to ineffective bacterial aggregation 
and oral clearance [134]. Inflammatory markers in the patients with BMS and 
the controls were also compared but no difference in the overall level of the 
markers was revealed. However, careful analysis of data suggested that the 
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patients with BMS represented a heterogeneous group as the inflammatory 
markers varied more within the BMS group compared to the control group. 
This suggests that subgroup of the BMS patients could arise from low-level 
inflammation in some cases, while non-inflammatory driven in others. This 
may be an effect of the increased low level inflammation reported to occur 
at various level due to aging [244]. 
It is possible that the subjective dryness sensed by the patients with BMS 
condition could be due to an inefficient lubrication of the oral mucosa as a 
result of reduced mucins and especially MUC5B. Reduced levels of MUC5B 
have been observed in patients with severe xerostomia [245]. The higher 
molecular-weight mucin MUC5B contains carbohydrates and has terminal 
sialylated and sulphated structure that retains large amount of water. Since 
MUC5B was not analysed at the structural level, it can only be speculated 
that this larger mucin may contribute to the dry mouth feelings. A significant 
reduction in the level of MUC5B in the UWS was observed in patients with 
OLP and the severity of xerostomia was correlated to the level of MUC5B in 
sera of the patients with OLP [246]. Exploration of MUC5B 
oligosaccharides is a potential target in BMS research in addition to the 
decreased Si-Lex on MUC7 as we report in Paper III. Overall, Paper III 
suggests that BMS patients are of heterogeneous in origin in terms of 
inflammatory markers they display. It further provides us the knowledge that 
in future studies, provided a reliable diagnosis, these patients can be stratified 
into further subgroups, to achieve personalised based therapy. Study III was 
done one a smaller subset of patients with BMS. However, studies like these 
with smaller number of patients are valuable in establishing a basis for 
further hypothesis-driven research and this in turn would enable to further 
carry out research in a larger cohort of patients and controls. 
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6 Main findings  
The main findings of the studies developed in this thesis are listed below, 
and an illustration of the overall significant findings is presented in Figure 
15. 
1. The most common pain sensation was a combination of burning 
and scalding sensation described by 37% of the patients with BMS, 
and 45% reported to experience taste disturbances (Paper I). 
2. The severity of BMS symptoms measured on a VAS scale on 
average was 66 (± 19.7 SD). About 80% of the patients reported 
their symptoms to be present  “always” and 66% patients reported 
to experience BMS symptoms both day and night (Paper I). 
3. Significantly fewer BMS patients than controls rated their general, 
oral health and life situation as satisfactory (Paper I). 
4. Higher proportion of patients reported to have skin diseases and 
xerostomia compared to the controls and the aforementioned 
factors were strongly associated to BMS (Paper I). 
5. Patients with BMS displayed less saliva on the tongue, less whole 
saliva, and more hyposalivation compared to the controls (Paper 
II). 
6. Less saliva in patients with BMS was related to more systemic 
diseases and medication (Paper II). 
7. Hyposalivation with very low SWS secretion rate in the patients with 
BMS was not associated to diseases and medication (Paper II). 
8. Xerostomia reported by BMS patients (Papers I and II) was not 
related to systemic diseases and medication (Paper II). 
9. Similar MUC7 oligosaccharides but significantly decreased 
fucosylated and sialylated oligosaccharide (e.g. Si-Lex) classes was 
seen in BMS (Paper III).  
10. The level of inflammatory markers was more heterogeneous in BMS 
compared to the controls (Paper III). 
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Figure 15. A schematic of the most significant findings from the work of this thesis Papers (I-III).  
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7 Conclusion and future perspectives 
This thesis explores three aspects of BMS: patients’ described and clinical 
characteristics, saliva secretion, and mucin component in saliva. BMS is a 
condition of diagnosed through exclusion, and therefore elucidating the 
clinical and socio-demographical/background characteristics of patients with 
BMS arms us with a better understanding of the condition. The findings 
from the explorative studies in this thesis provide the basis for defining the 
clinical and salivary parameters in BMS, which may contribute to a future 
model for BMS. Xerostomia and skin diseases are significant findings in this 
study. Another interesting finding is that BMS was not related to 
parafunction.  
Accounting for potential confounding factors, such as age, total number of 
drugs, and drugs having a reported adverse effect on the salivary secretion 
and oral mucosal blood flow, allowed a comprehensive comparison of the 
saliva of patients with BMS and controls. Although xerostomia was strongly 
associated to BMS, the factors such as medicines and systemic diseases did 
not have an impact in BMS group. Further studies are needed to elucidate 
whether other factors than objective salivary flow-rate, medicines and 
systemic diseases would affect xerostomia. Salivary constituents from the 
minor salivary glands, e.g., MUC5B and sIgA, are important for mucosal 
hydration/lubrication and mucosal immunity, respectively, and they are of 
interest to examine in patients with BMS and controls. In addition, results 
from work described in current thesis encourages us to carry out the 
inflammatory biomarker analysis on a larger cohort of patients with BMS 
with a wider age range, that in the future may aid in the classification of 
inflammatory and non-inflammatory driven BMS. This could increase our 
knowledge on the effect of inflamm-aging in BMS. Furthermore, reduced 
sialylated structures, such as Si-Lex, may suggest ineffective hydration of the 
oral mucosal surfaces. 
While not life threatening, BMS is a debilitating condition for the patients 
and different group of people show different symptoms. A thorough 
understanding of the pathogenesis and aetiology of BMS, along with novel 
diagnostic methods and development of therapeutic interventions is 
necessary for the management of BMS. Even if the present studies are well 
designed in terms of using age- and sex-matched case-controls, the results 
cannot be applied to a general population because men were excluded. Thus, 
the findings presented in this thesis not only provide new knowledge, but 
also raise new and interesting questions in the field of BMS. 
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10  Appendices 
Appendix 1. Complete Blood Count (CBC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hb: Haemoglobin 
LPC: Leukocyte particle count 
TPC: Thrombocyte particle count 
EPC: Erythrocyte particle count 
MCV: Mean corpuscular volume 
MCH: Mean corpuscular haemoglobin  
MCHC: Mean corpuscular haemoglobin concentration 
S-CRP: Serum C-reactive protein
Component Unit Reference range 
Reticulocytes x109/L 20-100 
Neutrophils x109/L 1.8-7.5 
Lymphocytes x109/L 0.8-4.5 
Monocytes x109/L 0.1-1 
Eosinophils x109/L 0.04-0.4 
Basophils x109/L 0-0.1 
Hb g/L 117-153 
LPC x109/L 3.5-8.8 
TPC x109/L 165-387 
EPC x1012/L 3.9-5.2 
MCV fL 82-98 
MCH pg 27-33 
MCHC g/L 317-357 
S-CRP mg/L <5 
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Appendix 3.  Allmänt frågeformulär 
 
 
1. Födelseår:___________ 
 
2. Civilstånd:  
 
  Gift  Skild  Singel  Särbo  Sambo  Änka/änkling 
 
3. Har ditt civilstånd förändrats de senaste 10 åren? 
 
  Ja  Nej 
 
 
4. Huvudsaklig sysselsättning de senaste 10 åren  
 (ex. typ av arbete/arbetslös/pensionär/sjukskriven)?  
 
  ________________________________________________________________________  
 
 
5. Bytt sysselsättning de senaste 10 åren (ex. bytt arbete/ blivit arbetslös/ blivit 
 pensionär/ blivit långtidssjukskriven)? 
 
  Ja  Nej 
 
6. Har du varit sjukskriven under den senaste 10-års perioden? 
 
  Nej 
  Ja, vid något enstaka tillfälle 
  Ja, några enstaka dagar då och då 
  Ja 
 
7. Hur skulle du beskriva din allmänna hälsa just nu? 
 
  Mycket god  God  Skaplig  Dålig  Mycket dålig 
 
8. Hur skulle du beskriva din munhälsa just nu? 
 
  Mycket god  God  Skaplig  Dålig  Mycket dålig 
 
9. Hur nöjd är du med din livssituation? 
 
  Mycket nöjd  Nöjd  Varken eller  Missnöjd  Mycket missnöjd 
 
10. Anser du dig fullt frisk? 
 
  Ja  Nej 
 
11. Har du någon eller några sjukdomar? 
 
  Ja  Nej 
 
 Om ja, vilken eller vilka? 
 
12. Har du haft några allvarliga sjukdomar? 
 
  Ja  Nej 
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 Om ja, vilken eller vilka? 
 
  ________________________________________________________________________  
 
13. Tar du regelbundet mediciner (även naturläkemedel, östrogenpreparat, p-piller etc)? 
 
  Ja  Nej 
 
 Om ja, vilken eller vilka? 
 
  ________________________________________________________________________  
 
14. Har du regelbunden menstruation? 
 
  Nej, slutat helt   Nej, oregelbunden   Ja 
 
15. Har du eller har haft övergångsbesvär? 
 
  Ja, har haft  Ja, har  Nej 
 
 Om ja, vilken typ av besvär? 
 
  ________________________________________________________________________  
 
16. Har du av din vårdgivare blivit rekommenderad östrogenbehandling för övergångsbesvär? 
 
  Nej  Ja, men ej använt  Ja, men slutat  Ja, använder nu 
 
17. Anser du dig vara infektionskänslig? 
 
  Ja  Nej 
 
Om ja, hur yttrar det sig? 
 
  ________________________________________________________________________  
 
18. Har du några hudsjukdomar eller hudbesvär? 
 
  Ja  Nej 
 
 Om ja, vilken eller vilka hudsjukdomar? Om hudbesvär, hur yttrar det sig? 
 
  ________________________________________________________________________  
 
19. Har du några besvär i underlivets slemhinna? 
 
  Ja  Nej 
 
 Om ja, hur yttrar det sig? 
 
  ________________________________________________________________________  
 
 
20. Går du på regelbundna vårdkontroller? 
 
  Ja  Nej 
 
 Om ja, vilken form av vårdkontakt och hur ofta? 
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  ________________________________________________________________________  
 
 
21. Är du allergisk mot något? 
 
  Ja  Nej 
 
 Mot vad? ________________________________________________________________  
 
 
22. Är du överkänslig mot någon medicin? 
  
  Ja  Nej 
 
 Om ja, vilken/vilka? _______________________________________________________  
 
 
23. Vad har du för tobaksvanor? 
 
  Jag har aldrig vanerökt 
  Jag slutade röka år:_____ 
  Jag röker ibland 
  Antal cig./vecka om du inte röker dagligen?_____ 
  Jag röker dagligen 
  Antal cigaretter/dag?_____ 
 
 
24. Hur många dagar per vecka är du fysiskt aktiv i sammanlagt 30 min?  
 (t.ex. promenad i rask takt) 
 
  1 dag   5 dagar 
  2 dagar  6 dagar 
  3 dagar  7 dagar 
  4 dagar 
 
25. Har du sömnproblem? 
 
  Ja  Nej 
 
 Om ja, hur ofta? 
 
  någon natt/mån  någon natt/vecka  nästan varje natt  varje natt 
 
 
 
 
26. Snarkar du när du sover? 
 
  Aldrig  Sällan  Ibland  Ofta  Alltid  Vet ej 
 
 
27. Andas du generellt sett mest genom munnen?  
 
  Aldrig  Sällan  Ibland  Ofta  Alltid  Vet ej 
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28. Upplever du att din urin är koncentrerad (stark lukt, kraftigt färgad)? 
 
  Aldrig  Sällan  Ibland  Ofta  Alltid  Vet ej 
 
 
29. Händer det att det känns som mängden saliv i munnen är för liten? 
 
  Ja  Nej 
 
Om du svarat ”nej” så hoppar du till fråga 37:  
 
 
30. Hur ofta är du muntorr? 
 
  Dagligen  Flera ggr/v  Någon ggn/v  Någon ggn/månad 
 
 
31. När på dygnet är du muntorr? 
 
  Alltid 
  Nästan jämt  
  Mest på natten 
  Mest på morgonen 
  Mest mitt på dagen 
  Mest på kvällen 
  Varierar  
 
32. Hur svåra är dina muntorrhetsbesvär? Markera med kryss på linjen.  
 
inte alls outhärdliga 
svåra 0 10 20 30 40 50 60 70 80 90 100 
 
 
33. Ungefär hur länge har du lidit av muntorrhet?______________ 
 
 
 
34. Upplever du att muntorrheten är ett problem när du intar en måltid?  
 
  Ja  Nej 
 
 
35. Har du problem att svälja föda som är torr? 
 
  Ja  Nej 
 
 
36. Behöver du dricka för att kunna svälja? 
 
  Ja  Nej 
37. Hur ont tycker du att det gör att ta ett blodprov i fingret? Markera med kryss på linjen. 
 
inte alls fruktansvärt  
ont 0 10 20 30 40 50 60 70 80 90 100  ont 
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38. (frågan kommer sist) 
 
 
39. Hur ofta och hur länge har Du haft något av följande besvär? 
 
 Aldrig 
eller 
sällan 
1-2 ggr 
per månad 
Någon ggn 
i veckan 
Några ggr 
i veckan 
Dagligen 
A) Trötthets/stelhetskänslor i 
     käkarna      
B) Käkledsknäppningar      
C) Skrapljud från käkleden      
D) Smärtor eller värk i ansikte 
    och käkar      
E) Huvudvärk      
F) Smärtor vid rörelse av  
    käken (gapa, tugga)      
G) Svårt att gapa stort,  
    gäspa el. bita stor tugga      
H) Käken hoppar ur led,  
    hakar upp sig el. låser sig      
I) Tandvärk      
J) Ilande och ömma tänder      
K) Migrän      
L) Yrsel      
M) Öronsusningar      
N) Tung- eller munsveda      
O) Besvär från nacken      
P) Ryggbesvär      
Q) Övrigt.: 
Vad?....................................... 
     
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Appendix 5. BMS-frågeformulär 
 
 
1. Hur yttrar sig dina BMS-symptom? 
 
  Brännande  Svidande  Domnat  Stickande 
 
2. Hur svåra är dina BMS-besvär besvär (intensitet)? Markera med kryss på linjen.  
 
inte alls outhärdliga 
svåra 0 10 20 30 40 50 60 70 80 90 100 
 
 
3. Hur ofta uppträder symptomen? 
 
  Då och då, men mkt sällan 
  Då och då, men sällan 
  Då och då, men ofta 
  Finns där alltid 
 
4. När på dygnet brukar symtomen uppträda? 
 
  På morgonen 
  Under dagen 
  På kvällen 
  Under natten 
  Både dag och natt 
 
5. Är det några faktorer som kan starta symtomen ex föda, medicin, stress? 
 
  Ja  Nej 
 
 Om ja, vilken/vilka?  
 
  ________________________________________________________________________  
 
 
6. Är det några faktorer som kan förvärra symtomen ex föda, medicin, stress? 
 
  Ja  Nej 
 
 Om ja, vilken/vilka?  
 
  ________________________________________________________________________  
 
 
7. Är det några faktorer som kan lindra symtomen ex föda, medicin, stress? 
 
  Ja  Nej 
 
 Om ja, vilken/vilka?  
 
  ________________________________________________________________________  
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8. Har du lagt märke till några smakförändringar? 
 
  Ja  Nej 
 
 Om ja, vilken/vilka?  
 
  ________________________________________________________________________  
 
9. Har du några andra symptom som du kopplar till din BMS? 
 
  Ja  Nej 
 
 Om ja, vilken/vilka?  
 
  ________________________________________________________________________  
 
10. När ungefär debuterade din BMS? 
 
 År: ________ 
 
11. Associerar du debuten av din BMS med någon speciell händelse (ex ny medicin, slutat 
 röka, förändrad levnadsförhållanden, dödsfall)? 
 
  Ja  Nej 
 
Om ja, vilken/vilka?  
 
_____________________________________________________________________ _______  
 
   
12. Om symptomen varierar över dygnet, när på dygnet har du mest besvär? 
 
  På morgonen 
  Under dagen 
  På kvällen 
  Under natten 
  Både dag och natt 
  Varierar 
 
13. Ungefär hur länge varar besvären om du inte har dem ständigt? 
 
 ______ timmar 
 ______ dagar 
 ______ veckor 
 ______ månader  
  Jag har dem ständigt  
 
14. Hur ofta har du besvär, om dina besvär inte är konstanta?  
 
 ______ gånger/dag 
 ______ gånger/vecka 
 ______ gånger/månad 
 ______ gånger/år 
  Jag har dem ständigt  
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15. Har du fått någon behandling för dina besvär som haft positiv effekt? 
 
  Ja  Nej 
 
 Om ja, vilken/vilka?  
 
  ________________________________________________________________________  
 
 
 
16. Har du någon anhörig eller släkting som lider av BMS? 
 
  Ja  Nej 
 
 Om ja, typ av släktskap?  _____________________________________________________  
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Appendix 7.                        ENKÄT OM MUNHÄLSA OCH LIVSKVALITÉ (OHIP) 
  
 
Detta är frågor som syftar till att utvärdera i vilken utsträckning Ditt munhälsotillstånd påverkar Din 
allmänna livssituation. 
 
Kryssa endast i ett alternativ per fråga. 
Exempel:       aldrig  sällan  ibland ofta  mycket ofta 
Har Du problem med att prata   □  □  □  □  □ 
beroende på problem med Dina  
tänder, munhåla eller proteser?    
 
     
       aldrig  sällan  ibland ofta  mycket ofta 
Under de senaste tre månaderna: 
 
1. Har Du haft svårigheter att   □  □  □  □  □ 
uttala något/några ord beroende 
på problem med Dina tänder,  
munhåla eller proteser? 
2. Har Du känt att Dina smak-  □  □  □  □  □ 
upplevelser har försämrats  
beroende på problem med Dina  
tänder, munhåla eller proteser? 
3. Har Du haft smärta från □  □  □  □  □ 
munhålan?  
4. Har Du upplevt svårigheter att äta □  □  □  □  □ 
någon föda beroende på problem  
med Dina tänder, munhåla eller  
proteser? 
5. Har Du upplevt osäkerhet   □  □  □  □  □ 
beroende på problem med Dina  
tänder, munhåla eller proteser? 
6. Har Du känt dig stressad beroende □  □  □  □  □ 
på problem med Dina tänder,  
munhåla eller proteser? 
7. Har Din diet varit otillfreds-  □  □  □  □  □ 
ställande beroende på problem 
med Dina tänder, munhåla eller  
proteser? 
8. Har Du avbrutit måltider beroende □  □  □  □  □ 
på problem med Dina tänder,  
munhåla eller proteser? 
         
               Vg vänd 
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       aldrig  sällan  ibland ofta  mycket ofta 
9. Har Du känt svårigheter att  □  □  □  □  □  
slappna av beroende på problem 
med Dina tänder, munhåla eller 
proteser? 
10. Har Du känt dig något genererad □  □  □  □  □ 
beroende på problem med Dina  
tänder, munhåla eller proteser? 
11. Har Du varit irriterad på andra □  □  □  □  □ 
människor beroende på problem  
med Dina tänder, munhåla eller  
proteser? 
12. Har Du haft svårt att genomföra □  □  □  □  □ 
 Dina vanliga sysslor beroende  
på problem med Dina tänder,  
munhåla eller proteser? 
13. Har du känt att Din allmänna  □  □  □  □  □ 
  livssituation varit mindre tillfreds- 
ställande beroende på problem med 
Dina tänder, munhåla eller proteser? 
 
14. Har det varit totalt omöjligt för □  □  □  □  □  
Dig att fungera i det dagliga livet  
beroende på problem med Dina  
tänder, munhåla eller proteser? 
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